0001575705-16-000167.txt : 20160809 0001575705-16-000167.hdr.sgml : 20160809 20160808213449 ACCESSION NUMBER: 0001575705-16-000167 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160809 DATE AS OF CHANGE: 20160808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: True Nature Holding, Inc. CENTRAL INDEX KEY: 0000802257 STANDARD INDUSTRIAL CLASSIFICATION: COMMUNICATIONS EQUIPMENT, NEC [3669] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53601 FILM NUMBER: 161815860 BUSINESS ADDRESS: STREET 1: 1355 PEACHTREE STREET STREET 2: SUITE 1150 CITY: ATLANTA STATE: GA ZIP: 30309 BUSINESS PHONE: 404-254-6980 MAIL ADDRESS: STREET 1: 1355 PEACHTREE STREET STREET 2: SUITE 1150 CITY: ATLANTA STATE: GA ZIP: 30309 FORMER COMPANY: FORMER CONFORMED NAME: Trunity Holdings, Inc. DATE OF NAME CHANGE: 20120125 FORMER COMPANY: FORMER CONFORMED NAME: BRAIN TREE INTERNATIONAL INC DATE OF NAME CHANGE: 19860922 10-Q 1 tnty_2q16.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended June 30, 2016

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number 000-53601

TRUE NATURE HOLDING, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		87-0496850

(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification Number)

1355 Peachtree Street, Suite 1150

Atlanta, Georgia 30309

(Address, including zip code, of principal executive offices)

Trunity Holdings, Inc.

12555 Orange Drive, Suite 202

Davie, Florida 33330

(Former name or former address if changed since last report.)

(404) 254-6980

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

☐	LARGE ACCELERATED FILER	☐	ACCELERATED FILER

☐	NON-ACCELERATED FILER	☒	SMALLER REPORTING COMPANY

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. YES ☐ NO ☒

As of August 8, 2016, 13,308,333 shares of the registrant’s common stock, $0.01 par value, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE: None

TRUE NATURE HOLDING, INC.

TABLE OF CONTENTS

		PAGE

PART I	FINANCIAL INFORMATION	3

Item 1.	Consolidated Financial Statements (Unaudited)	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

PART II	OTHER INFORMATION	24

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	26

Item 4.	Mine Safety Disclosures	26

Item 5.	Other Information	26

Item 6.	Exhibits

	Signatures	30

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

TRUE NATURE HOLDING, INC.

Consolidated Balance Sheets

	June 30,			December 31,
	2016			2015
	(unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	20,571		$	28,185
Accounts receivable		26,000			—
Inventory		111,668			—
Prepaid expenses and other current assets		30,179			—
Prepaid expenses - related party		—			17,000
Total current assets		188,418			45,185

Property and equipment, net		5,294			—
Customer relationships		151,273			—
Goodwill		561,430			—

TOTAL ASSETS	$	906,415		$	45,185

LIABILITIES
Current liabilities
Accounts payable	$	600,647		$	414,463
Short-term loan		44,350			—
Accrued interest		24,600			14,918
Accrued liabilities		46,569			13,325
Debentures payable		122,167			122,167
Convertible note payable, net of discount		224,962			—
Total current liabilities		1,063,295			564,873

TOTAL LIABILITIES		1,063,295			564,873

Commitments and Contingencies (Note 12)

STOCKHOLDERS’ DEFICIT
Preferred stock, $0.01 par value - 10,000,000 shares authorized, none issued and outstanding as of June 30, 2016 and December 31, 2015		—			—
Common stock, $0.01 par value – 500,000,000 shares authorized, 13,175,000 shares issued and outstanding at June 30, 2016; $0.01 par value – 500,000,000 shares authorized, 11,765,000 shares issued and outstanding at December 31, 2015		131,750			117,650
Additional paid-in capital		3,119,918			3,917
Accumulated deficit		(3,408,548	)		(641,255	)
Total Stockholders’ Deficit		(156,880	)		(519,688	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	906,415		$	45,185

The accompanying notes are an integral part of the Consolidated Financial Statements.

TRUE NATURE HOLDING, INC.

Unaudited Consolidated Statements of Operations and Comprehensive Loss

	For the Three Months						For the Six Months
	June 30,			June 30,			June 30,			June 30,
	2016			2015			2016			2015
Net Sales	$	—		$	—		$	—		$	—
Cost of sales		—			—			—			—
Gross Profit		—			—			—			—

Operating Expenses:
Research and development		—			—			—			—
Selling, general and administrative		1,679,986			—			2,512,355			—
Total operating expenses		1,679,986			—			2,512,355			—

Operating Loss from Continuing Operations		(1,679,986	)		—			(2,512,355	)		—
Interest expense, net		(58,720	)		—			(64,938	)		—
Loss on debt extinguishment		(190,000	)		—			(190,000	)		—
Loss From Continuing Operations before Income Taxes		(1,928,706	)		—			(2,767,293	)		—
Provision for income taxes		—			—			—			—
Net Loss From Continuing Operations	$	(1,928,706	)	$	—			(2,767,293	)		—

Discontinued Operations (Note 5):
Net Loss from discontinued operations, net of tax		—			(699,729	)		—			(1,322,199	)
Other comprehensive gain, net of tax		—			14,082			—			12,807
Comprehensive Loss from Discontinued Operations	$	—		$	(685,647	)		—			(1,309,392	)

Net Loss	$	(1,928,706	)	$	(699,729	)		(2,767,293	)		(1,322,199	)
Comprehensive Net Loss	$	(1,928,706	)	$	(685,647	)		(2,767,293	)		(1,309,392	)


Net Loss from Continuing Operations Per Share – Basic and Diluted	$	(0.15	)	$	—			(0.22	)		—
Net Loss from Discontinued Operations Per Share – Basic and Diluted	$	—		$	(1.28	)		—			(2.43	)
Net Loss Per Share – Basic and Diluted	$	(0.15	)	$	(1.28	)		(0.22	)		(2.43	)

Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted		12,687,478			545,386			12,368,961			543,996

The accompanying notes are an integral part of the Consolidated Financial Statements.

TRUE NATURE HOLDING, INC.

Unaudited Consolidated Statements of Changes in Stockholders’ Deficit

	Common Shares		Common Stock		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders’ Deficit
Balance at January 1, 2016		11,765,000	$	117,650	$	3,917	$	(641,255	)	$	(519,688	)
Sale of common stock, net of issuance cost		120,000		1,200		49,800		—			51,000
Shares issued to board members		400,000		4,000		723,000		—			727,000
Shares issued to consulting members		410,000		4,100		402,400		—			406,500
Shares issued for P3 Compounding of Georgia acquisition		340,000		3,400		258,400		—			261,800
Shares issued to employee		125,000		1,250		433,750		—			435,000
Common stock issued for convertible note payable		15,000		150		16,213		—			16,363
Discount related to issuance of notes payable and allocated fair value to beneficial conversion feature		—		—		533,804		—			533,804
Loss on debt extinguishment		—		—		190,000		—			190,000
Stock compensation expense		—		—		508,634		—			508,634
Net loss		—		—		—		(2,767,293	)		(2,767,293	)
Balance at June 30, 2016		13,175,000	$	131,750	$	3,119,918	$	(3,408,548	)	$	(156,880	)

The accompanying notes are an integral part of the Consolidated Financial Statements

TRUE NATURE HOLDING, INC.

Unaudited Consolidated Statements of Cash Flows

	For the Six Months Ended
	June 30,			June 30,
	2016			2015
Cash Flows from Operating Activities:
Net Loss	$	(2,767,293	)	$	(1,322,199	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations		—			1,322,199
Accretion for debt discounts, warrants and issuance costs		40,129			—
Stock-based option compensation		508,634			—
Shares issued for board of director compensation		727,000			—
Shares issued for consulting services		406,500			—
Shares issued to employee		435,000			—
Loss on debt extinguishment		190,000			—
Changes in operating assets and liabilities:
Prepaid expenses and other assets		7,527			—
Accounts payable		150,762			—
Accrued interest and other liabilities		42,926			—
Net Cash Used in Operating Activities	$	(258,815	)	$	—

Cash Flows from Investing Activities:
Cash received from acquisition of P3 Compounding of Georgia		10,201			—
Net Cash Provided by Investing Activities	$	10,201		$	—

Cash Flows from Financing Activities:
Proceeds from issuance of convertible note payable		160,000			—
Sale of common stock, net of issuance costs		51,000			—
Proceeds from short-term loan		30,000			—
Net Cash Provided by Financing Activities	$	241,000		$	—
Discontinued Operations:
Operating activities		—			(239,974	)
Investing activities		—			(72,983	)
Financing activities		—			314,838
Net Increase in Cash and Cash Equivalents for Discontinued Operations		—			1,881
Net Decrease in Cash and Cash Equivalents for Continuing Operations		(7,614	)		—
Cash, Beginning of Period		28,185			14,119
Cash, End of Period	$	20,571		$	16,000

Non-cash Investing and Financing Transactions:
Conversion of debt to common stock shares	$	—		$	45,953
Discount cost related to issuance of convertible notes payable	$	575,167		$	274,122
Acquisition of P3 Compounding of Georgia, net of cash acquired:
Fair value of assets acquired	$	314,941		$	—
Fair value of liabilities assumed	$	35,422		$	—
Issuance of common stock for acquisition of P3	$	261,800		$	—
Debt obligation recorded as a result of acquisition	$	589,350		$	—
Goodwill	$	561,430		$	—

The accompanying notes are an integral part of the Consolidated Financial Statements.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 1 – Description of Business

True Nature Holding, Inc. is executing on a business plan to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals. The Company completed its first acquisition of P3 Compounding in June 2016 and is pursuing a series of compounding pharmacy acquisitions.

True Nature Holding, Inc. (the “Company”), previously known as Trunity Holdings, Inc., became a publicly-traded company through a reverse merger with Brain Tree International, Inc., a Utah corporation (“BTI”). Trunity Holdings, Inc. was the parent company of the prior educational business, named Trunity, Inc., which was formed on July 28, 2009 through the acquisition of certain intellectual property by its three founders. On December 31, 2015, the Company completed the restructuring and spin-out of the educational business.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position at June 30, 2016, the results of operations for the three months and six months ended June 30, 2016 and 2015, and cash flows for the three months and six months ended June 30, 2016 and 2015. The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s audited consolidated financial statements and management’s discussion and analysis included in the Company’s annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 5 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.

Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments.

The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of June 30, 2016, the Company had 142,652 warrants, 1,067,879 options, 135,037 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of June 30, 2015, the Company had 77,640 warrants, 67,483 options, 316,721 potential shares which may be issued resulting from the provisions of convertible notes, respectively.

Accounts Receivable - The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Accounts receivable are stated at the invoiced amount and are unsecured and require no collateral. Charges to bad debt are based on both historical write-offs and specifically identified receivables.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 2 – Summary of Significant Accounting Policies- Continued

Inventories - Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. In addition, the Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.

Property and Equipment, net - Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed generally on a straight-line basis over the estimated useful lives of the assets. The cost of leasehold improvements are amortized either over the life of the improvement or the lease term, whichever is shorter. Significant improvements are capitalized and disposed or replaced property is written off. Maintenance and repairs are charged to expense in the period they are incurred. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts, and any gain or loss is included in earnings.

Business Combinations - The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts; and discount rates utilized in valuation estimates.

Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.

Goodwill and Intangible Assets - Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill and intangibles under ASC Topic 350, Intangibles – Goodwill and Other, which does not permit amortization, but requires the Company to test goodwill and other indefinite-lived assets for impairment annually or whenever events or circumstances indicate impairment may exist.

Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 2 – Summary of Significant Accounting Policies-Continued

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective for annual periods beginning on or after December 15, 2016, including interim periods within those annual periods. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.

In August 2014, the FASB issued new accounting guidance which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Company’s consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Company’s cash flows.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

Note 3 – Recent Developments

On April 4, 2016 the Company entered into a non-binding letter of intent to acquire Cherokee Compounding Pharmacy in Holly Springs, Georgia, a suburb of Atlanta. The agreement calls for purchase consideration of approximately $450,000. Payment will be split between cash and the issuance of common stock. The final allocation of each of these will be determined prior to closing, which is expected to occur in third quarter 2016. The letter of intent is not a definitive agreement, and the Company expects to execute a definitive agreement at closing.

On May 20, 2016 the Company entered into a non-binding letter of intent to acquire Innovation Compounding, Inc. (“Innovation”) in Kennesaw, Georgia. The Company incurred $30,000 of expenses related to a fee for a “no-shop” provision, in addition to other customary expenses associated with the due diligence process. Management has determined not to pursue this acquisition further at this time.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 4 – Financial Condition and Going Concern

As of June 30, 2016, the Company had cash on hand of $20,571 and current liabilities of $1,063,295 and has incurred a loss from operations. True Nature Holding’s principal operations is the acquisition of compounding pharmacy companies. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered into discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists.

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

Note 5 – Spin-Out and Discontinued Operations

On December 31, 2015, the Company completed the restructuring and spin-out of its software educational business, resulting in True Nature Holding, Inc. becoming purely focused on acquiring a series of compounding pharmacy businesses, largely direct to consumers, doctors and veterinary professionals. The results of the operations associated with the spin-out company and Trunity Holdings, Inc., qualifies as discontinued operations as of and for the three and six month periods ended June 30, 2015.

The results of operations associated with discontinued operations were as follows:

	Three Months Ended			Six Months Ended
	June 30, 2015			June 30, 2015
Net Sales	$	66,458		$	185,137
Cost of sales		27,894			90,023
Gross Profit		38,564			95,114

Operating Expenses:
Research and development		186,950			381,649
Selling, general and administrative		232,596			484,862
Total operating expenses		419,546			866,511

Operating Loss from Discontinued Operations		(380,982	)		(771,397	)

Other Expense:
Interest expense, net		(318,747	)		(550,802	)

Net Loss from Discontinued Operations	$	(699,729	)		(1,322,199	)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		14,082			12,807
Comprehensive Loss from Discontinued Operations	$	(685,647	)	$	(1,309,392	)

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 5 – Spin-Out and Discontinued Operations (continued)

Our educational business was fully disposed of in December 2015. As a result, there were no assets or liabilities of discontinued operations as of December 31, 2015 or in subsequent periods.

Note 6 - Acquisition

On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC, (“P3”). P3 received Georgia Board of Pharmacy approval for the transaction at the end of June 2016 and the transaction closed effective June 30, 2016. P3 is a full service compounding pharmacy with both sterile and non-sterile expertise headquarter in Atlanta, Georgia. The medicines that P3 compounds include bio-identical hormone replacement therapy, transdermal pain creams, wellness compounding, individualized and prescriptions. The transaction included the acquisition of identifiable assets, customer listings and intellectual properties included in the P3’s library of specialized formulations.

As a result of the acquisition, P3 is now a wholly owned subsidiary of the Company. The acquisition of P3 permits the Company to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions through P3 and introduces the Company to new geographic and compounded formulation markets.

The transaction has been accounted for as a business combination and recorded as of June 30, 2016, therefore no revenues or net income have been included in the Company’s consolidated financial statements for second quarter 2016.

The fair value of the consideration paid pertaining to the acquisition of P3 was $851,150. Consideration for the transaction was structured as follows:

	■	An interest-free note for $150,000 with no interest to be paid in full via wire transfer on the maturity date of August 16, 2016;

	■	$425,000 convertible note with a term of 12 months and a 6% interest rate, with the first installment due June 1, 2016, and convertible into common stock of True Nature at a rate of $1.25 per share (which is 340,000 shares of common stock), less a short-term financing for $14,350 that the Company provided to Integrity for working capital purposes;

	■	A $425,000 convertible note with no interest, which automatically converted 340,000 shares of common stock with a fair value of $261,800 based on the closing price of the True Nature’s common stock on June 30, 2016.

The notes issued in conjunction with the purchase and the intellectual properties may be converted into restricted common stock at a rate of $1.25 per share. The purchase includes all payables, receivables, cash on hand, inventory and all assets used in the operation of the business.

In addition, Mr. Casey Gaetano, a former owner of P3, received an employment contract with True Nature for 3 years as VP of Corporate Development, at an annual salary of $125,000, plus normal benefits commensurate with other executives in the Company of equal stature. He also receive in second quarter 2016, 125,000 shares of restricted at a value of $3.48 per share in exchange for becoming the Company’s VP of Corporate Development.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 6 - Acquisition-Continued

Allocation of Consideration Transferred

The identifiable assets acquired and liabilities assumed were recognized and measured as of the acquisition date based on their estimated fair values as of June 30, 2016. The excess of the acquisition date fair value of consideration transferred over the estimated fair value of the net tangible assets and intangible assets acquired was recorded as goodwill.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date based on a fair value acquisition price of $851,150 pertaining to the consideration provided.

Cash and cash equivalents	$	10,201
Accounts receivable		26,000
Inventories		111,668
Other current assets		20,706
Furniture and equipment		5,294
Customer list		151,273
Total identifiable assets acquired		325,142
Accounts payable and accrued expenses		35,422
Total liabilities assumed		35,422
Total identifiable assets less liabilities assumed		289,720
Goodwill		561,430
Net assets acquired	$	851,150

The fair value of the transaction and related purchase price allocation was based on a third-party valuation obtained by the Company.

Intangible Assets-Customer Relationships

In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of the acquired assets, analyses of historical financial performance of P3 and estimates of future performance of P3. The fair values of the identified intangible assets related to P3’s customer relationships. Customer relationships were calculated using the income approach. The following table sets forth the components of identified intangible assets associated with the P3 Acquisition and their estimated useful lives.

	Fair Value		Useful Life
Customer relationships	$	151,273	7 years
	$	151,273

The Company determined the useful lives of intangible assets based on the expected future cash flows and contractual life associated with the respective assets. Customer relationships represent the expected future benefit from contracts and relationships which, at the date of acquisition, were reasonably anticipated to continue given the history and operating practices of P3.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 6. Acquisition-Continued

Goodwill

Of the total estimated purchase price for the P3 Acquisition, $561,430 was allocated to goodwill. Goodwill represents the excess of the purchase price of the acquired business over the fair value of the underlying net tangible and intangible assets acquired. The goodwill recorded resulting from the acquisition is expected to be deductible for income tax purposes.

Note 7 – Related Party Transactions

The Company’s Chairman of the Board and CFO, Stephen Keaveney has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $10,000 and $26,000, respectively during the three and six months ending June 30, 2016. The Company’s newly appointed CEO, James Driscoll has an employment agreement effective June 7, 2016 that will pay him a monthly salary in the amount of $12,500 per month for remainder of 2016, $17,500 per month for the calendar year of 2017, $22,500 per month for the calendar year of 2018 and $25,000 per month for the calendar year of 2019. No payments have been made to James Driscoll during the three and six months ending June 30, 2016.

On January 25, 2016 board member William L. Ross and Jeffrey Cosman were each awarded 100,000 of shares of the Company in exchange for their services as board members. On April 25, 2016 board member James Driscoll was awarded 100,000 of shares of the Company in exchange for his services on the board and 1,000,000 non-qualified stock options for his position as CEO. On May 25, 2016, board member Phillip Crone was awarded 100,000 of shares the Company in exchange for his services on the board.

In addition, a shareholder of the Company has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $1,395 and $18,645 during the three and six months ended June 30, 2016, respectively. As of December 31, 2015, $17,000 was classified as a prepaid asset in the consolidated balance sheets related to the prepayment of consulting fees. No amounts were prepaid as of June 30, 2016.

Any amount owed for services performed through June 30, 2016 and remain unpaid are recorded as accrued labilities on the consolidated balance sheets.

Note 8 – Debt

Convertible Promissory Notes

On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the “Convertible Note A”) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note A, on the date thereof, the Company issued the Convertible Note A to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note A. Upon issuance the lender was awarded 15,000 restricted common shares as an origination fee which have certain registration rights.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 8 – Debt-Continued

The beneficial conversion feature of $16,364 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of June 30, 2016, the carrying value of this Convertible Note A was $45,872 and accrued interest expense of $1,080. For the three and six months ended June 30, 2016, debt discount amortization related to the Convertible Note A was $16,274 and $18,599, respectively and its related interest expense was $1,820 and $2,080, respectively.

On May 19, 2016, the Company issued a 10% Convertible Promissory Note (the “Convertible Note B”) in the principal amount of $100,000 to the Lender. Pursuant to the terms of the Convertible Note B, on the date thereof, the Company issued the Convertible Note B to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note B. Upon issuance the lender was awarded 66,666 warrants to purchase common stock of the Company at an exercise price of $2.50 for a term of twenty-four months.

Pursuant to the terms of the Convertible Note B, the Company is obligated to repay the full principal amount of the Convertible Note B with any unpaid interest upon the date of maturity, June 19, 2017. The Convertible Note B is convertible by the holder at any time into shares of the Company’s common stock at an effective conversion price of $1.50 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note B to the shares and the note based on relative fair values, and the amount allocated to the shares of $39,887 was recorded as a discount against the note, with an offsetting entry to additional paid-in capital. The beneficial conversion feature of $52,553 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of June 30, 2016, the carrying value of this Convertible Note B was $29,090 and accrued interest expense of $1,167. For the three and six months ended June 30, 2016, debt discount amortization related to the Convertible Note B was $21,530 and its related interest expense was $1,167.

Short-term Loan

As a result of the acquisition of P3 Compounding of Georgia, LLC the Company had a short-term loan with a loan agency for a principal amount of $52,000 for the purchase of future sales and credit card receivables of P3. Under the terms of the receivable purchase agreement, the Company purchased an advance of $50,000 plus $2,000 for origination costs with a 10.5% daily interest rate to be repaid over 160 days at a repayment amount of $451.75 per day. Upon maturity of the loan the total repayment amount will be $72,280. As of June 30, 2016, the carrying value of this short term loan was $44,350. For the three and six months ended June 30, 2016, no interest expense related to this loan was recorded in the Company’s consolidated financial statements as the effective date of acquisition was the last day of the quarter.

August 2014 Convertible Debentures (Series C)

In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion; however, one debenture holder that was issued a Series C Convertible Debenture (the “Series C Debenture”) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured on October 31, 2015, and is convertible into the Company’s common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of June 30, 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $19,950. For the three and six months ended June 30, 2016, interest expense related to the Debenture was $3,325 and $6,613, respectively.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 8 – Debt-Continued

November 2014 Convertible Debentures (Series D)

In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the “Series D Debenture”) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,334 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured on October 31, 2015, and is convertible into the Company’s common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of June 30, 2016, the carrying value of the Series D Debenture was $11,334 and accrued interest expense of $2,267. For the three and six months ended June 30, 2016, interest expense related to the Debenture was $340 and $686, respectively.

Note 9 – Stockholders’ Deficit

Sale of Common Stock – During the six months ended June 30, 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. The Company incurred $9,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.

Shares for Consulting Services and Board Members – During the six months ended June 30, 2016, in connection with services rendered, the Company issued 410,000 restricted shares of the Company’s common stock at values of $2.90, $1.45 and $0.90 per share in exchange for financial consulting and legal services conducted on behalf of the Company. In addition, in connection with services rendered for board members, the Company issued 400,000 restricted shares of the Company’s common stock at values of $1.45, $2.02 and $2.35 per share in exchange for their services conducted on behalf of the Company. The issuance of these shares were recorded at the fair value of the shares at the date of issuance.

Shares for Employee – During the six months ended June 30, 2016, in connection with employment contract, the Company issued 125,000 restricted shares of the Company’s common stock at a value of $3.48 per share in exchange for Casey Gaetano becoming the Company’s VP of Corporate Development.

Shares issued for convertible note payable – As discussed in Note 8, during the six months ended June 30, 2016, in connection with conversion of a six-month convertible promissory note, the Company issued 15,000 shares of the Company’s common stock with a fair value of $16,363 that was allocated based on the relative fair value of the note and associated shares.

Debt beneficial conversion feature for convertible note payable – During the six months ended June 30, 2016, the Company raised gross proceeds of $160,000 pursuant to two Convertible Notes Payable (“Notes”) that allocated the face value of the Note to the shares and debt based on their relative fair values and, resulted in the recording of beneficial conversion features totaling $108,804 as a discount against the Notes, with an offsetting entry to additional paid-in capital. The discount is being amortized into interest expense over the term of the Notes.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 9 – Stockholders’ Deficit- Continued

Shares issued for convertible note payable of acquisition of P3 Compounding of Georgia, LLC- As part of the consideration for the acquisition of P3 a convertible note in the amount of $425,000 was converted into common stock of the Company at price per share of $1.25 resulting in the issuance of 340,000 shares of common stock.

Note 10 – Stock-Based Compensation

The Company has two Employee, Director and Consultant Stock Option Plans that were not terminated as a result of the fiscal 2015 restructuring of the Company and spin-out and have continued as part of the operations as detailed below.

In fiscal 2015, the option pool pertaining to the 2009 Employee, Director and Consultant Stock Option Plan (the “2009 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized option pool of 18,152. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of June 30, 2016 there were 3,610 shares available for future awards under this plan.

In fiscal 2015, the option pool pertaining to the 2012 Employee, Director and Consultant Stock Option Plan (the “2012 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized options pool of 74,257. Stock options typically vest over a three year period and have a life of ten years from the date granted. As of June 30, 2016, there were 45,673 shares available for future awards under this plan.

In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of spin-out Company in fiscal 2014. These options issued are outside of the 2009 and 2012 Plans.

On June 1, 2016 Jim Driscoll was granted for his position as Chief Executive Officer (CEO) of the Company options to purchase up to 1,000,000 shares of Common Stock outside of the Company’s 2009 and 2012 stock option plans (the “Option Agreement”). These options covered 250,000 shares at an exercise price of $1.00 per share to be granted immediately and three additional tranches of 250,000 shares each at an exercise price of $1.50, $2.00 and $2.50 per share, respectively. The remaining three tranches will vest equally over the next three years with the first fully vesting on May 31, 2017 through May 31, 2019. The term of the options will be for a period of five years and may be exercised at any time as to the vested shares.

During the three and six months ended June 30, 2016, the Company recorded stock compensation expense related to the options granted to Mr. Driscoll of $496,668 and has unrecognized stock expense of $1,040,793 to be recorded over the vesting period. The grant-date fair value of options was estimated using the Black-Scholes option pricing model. The per share weighted average fair value of stock options granted for Mr. Driscoll was a range of $1.35-$1.76 and was determined using the following assumptions: expected price volatility is 80.39%, risk-free interest rate of 1.39%, zero expected dividend yield, and 4.0 years expected life of options. The expected term of options granted is based on the simplified method in accordance with Securities and Exchange Commission Staff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. The Company makes assumptions with respect to expected stock price volatility based on the average historical volatility of peers with similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturities similar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day.

As of June 30, 2016, unrecognized stock compensation expense related to unvested stock options under all Plans was $1,041, 377. This expense is expected to be recognized over the remaining weighted average vesting periods of the outstanding options of 1.92 years. Total stock compensation expense recorded to selling, general and administrative expenses on the consolidated statements of operations and comprehensive for the six month period ending June 30, 2016 related to the all Plans and options that vested during the period was $508,634.

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 10 – Stock-Based Compensation-Continued

A summary of options issued, exercised and cancelled are as follows:

	Shares		Weighted- Average Exercise Price ($)		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2015		67,879	$	21.40		7.17		—
Granted		1,000,000		1.75		5.00		—
Cancelled		—		—		—		—

Outstanding at June 30, 2016		1,067,879	$	3.00		5.22		—

Exercisable at June 30, 2016		354,911	$	4.99		4.95		—

Note 11 – Warrants to Purchase Common Stock

Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized. All warrants outstanding as of June 30, 2016 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows:

	Shares			Weighted- Average Exercise Price ($)		Weighted- Average Remaining Contractual Term
Outstanding at December 31, 2015		78,462		$	29.55		3.43
Granted		66,666			2.50		2.00
Expired		(2,475	)		50.50		—

Outstanding at June 30, 2016		142,653		$	17.42		2.50

Exercisable at June 30, 2016		142,653		$	17.42		2.50

TRUE NATURE HOLDING, INC.

Notes To Consolidated Financial Statements

(Unaudited)

Note 12 – Commitments and Contingencies

Legal

National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No.. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division.

This action was filed on December 16, 2015 by the National Council for Science and the Environment, Inc. (“NCSE”) in the state court in the District of Columbia against Trunity Holdings, Inc. (“Trunity”) and alleges claims for Breach of Contract. Acknowledgement of Indebtedness and Settlement Agreement and Quantum Meruit arising out of an agreement entered into between NCSE and Trunity in 2014. The Complaint seeks damages in the amount of $177,270, inclusive of attorney’s fees, costs and accrued interest, continuing interest in the amount of 12% per annum and attorney’s fees and costs of collection relating to the case. The Company in its answer on January 27, 2016, denied the material allegations made by NCSE, asserted a number of affirmative defenses and filed a counterclaim alleging claims for fraud, negligent misrepresentation, breach of fiduciary duty, breach of contract and unjust enrichment. In its counterclaim, the Company will seek actual and compensatory damages against NCSE that it believes exceed the amount sought by NCSE on its claims, pre-judgment interest, punitive damages and all costs and expenses, including attorney’s fees, incurred by the Company in bringing its claims against NCSE.

On February 19, 2016, NCSE filed a motion to dismiss the counterclaim, and the Company has filed its brief in the opposition to that motion. A hearing is scheduled in 2016 on the motion. No discovery has been conducted by the parties yet, and no trial date has been set by the court. We have recorded a liability as of June 30, 2016 based on our best estimate of the probable exposure pertaining to the claim.

Note 13 – Subsequent Events

On July 6, 2016, the Company appointed Gary Meyer to the newly created position of Director of Compliance, providing oversight to its compounding pharmacy operations in the area of licensing, operational compliance and to interface with the appropriate regulatory bodies at the state and federal level. He worked as a Pharmacist in Charge for CRC Pharmacy from Aug 2015 to July 2016, Physicians Rx Pharmacy from April 2015 to July 2015, Dunwoody Pharmacy from 1995 to Feb 2015, Concord Pharmacy from 1992 to 1995 and Kroger Pharmacy in 1992.

Mr. Meyer has a bachelor’s of Science in Pharmacy from The University of Georgia. Mr. Meyer holds a Georgia Board of Pharmacy license 1989- current, is a Past Board Member of the Pharmacy Franchise & Owners Association, a member of National Community Pharmacists Association, a member of Georgia Pharmacy Association, Member of the International Academy of Compounding Pharmacists, Member since 1995 of the Professional Compounding Centers of America, . He will report to the Company’s CEO, James Driscoll. As part of his employment agreement he will receive 50,000 shares.

On August 2, 2016, the Board of Directors approved the consulting agreement with Acorn Management for market awareness, which calls for monthly payments starting at $7,500 per month and restricted common shares to be valued at $50,000 per month to be converted at fair value at month-end.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report on Form 10-Q (this “Quarterly Report”). Our consolidated financial statements have been prepared and, unless otherwise stated, the information derived therefrom as presented in this discussion and analysis is presented, in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

The information contained in this Quarterly Report is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and subsequent reports on Form 8-K, which discuss our business in greater detail. Unless the context indicates otherwise, the “Company”, “we”, “us”, and “our” in this Item 2 and elsewhere in this Quarterly Report refer to True Nature Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries.

In addition to historical information, the following discussion contains forward-looking statements regarding future events and our future performance. In some cases, you can identify forward-looking statements by terminology such as “will”, “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “forecasts”, “potential” or “continue” or the negative of these terms or other comparable terminology. All statements made in this Quarterly Report other than statements of historical fact are forward-looking statements. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, risks related to: our ability to successfully implement our business plan, develop and commercialize our proprietary formulations in a timely manner or at all, identify and acquire additional proprietary formulations, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally; our limited operating history; and the other risks and uncertainties described under the heading “Risk Factors” in Part II, Item 1A of this Quarterly Report. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made and, except as required by law, we undertake no obligation to revise or publicly update any forward-looking statement for any reason.

Overview

We are an early stage company that intends to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, and to doctors and veterinary professionals.

Description of Pharmaceutical Compounding

The vast majority of medications are mass-produced by pharmaceutical drug companies. They aim to treat a specific medical condition for a large segment of people. Problems can arise when a patient has a medical condition that can’t be treated by one of these mass-produced products. Pharmaceutical compounding (done in compounding pharmacies) is the creation of a particular pharmaceutical product prescribed by doctors to fit the unique needs of a patient that can’t be met by commercially available drugs. To do this, compounding pharmacists combine or process appropriate ingredients using various tools. This may be done for medically necessary reasons, such as to change the form of the medication from a solid pill to a liquid, to avoid a non-essential ingredient that the patient is allergic to, or to obtain the exact dose(s) needed or deemed best of particular active pharmaceutical ingredient(s). It may also be done for more optional reasons, such as adding flavors to a medication or otherwise altering taste or texture. Examples of compounded formulations include medications with alternative dosage strengths or unique dosage forms, such as topical creams or gels, suspensions or solutions with more tolerable drug delivery vehicles. Compounding pharmacies (and pharmacists) adhere to standards and regulations set by the U.S. Pharmacopeia, National Association of Boards and State Boards of Pharmacy for quality assurance and accuracy. The compounding pharmacy business has the potential to provide high margins, and allow the pharmacy to specialize is certain solutions for specific maladies, so it can target specific markets efficiently.

We intend to focus on the acquisition of compounders who have a) a large client base in the veterinary area, b) a strong set of proprietary compounding solutions, versus non-proprietary “over-the-counter” (OTC) medicine sales, and c) where the combination of incremental operations will allow cross selling of a growing line of proprietary compounds into the respective markets of each new market participant acquired.

We expect economies of scale from the consolidation of:

●	Materials procurement;
●	Compounding activities combined into larger, more efficient and higher quality facilities;
●	Expanded marketing nationwide with an emphasis on densely populated urban areas where an expanded product line may increase the profitability of each individual branch, when compared to pre-acquisition sales, and;
●	Consolidated administration and personnel functions.

Off-Balance Sheet Arrangements

Since our inception, except for standard operating leases, we have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities. We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

In the second quarter of 2016, there were no significant changes to our critical accounting policies and estimates from those disclosed in the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2015 Form 10-K.

Recently Issued and Adopted Accounting Pronouncements

See Note 2 to our consolidated financial statements included in this Quarterly Report.

Results of Operations

The following period-to-period comparisons of our financial results are not necessarily indicative of results for the current period or any future period. In particular, our pharmacy operations activities will commence in the third quarter of 2016 and we have spun-out the prior year educational business which is presented as discontinued operations in the consolidated financial statements. This change in the nature of our operations will have and is expected to continue to have a significant impact on our financial results. As a result, our results of operations in the periods after commencement of our pharmacy operations will include aggregate revenue and expense amounts and the apportionment of expenses among categories, have changed and are expected to continue to change as we further develop these operations. Further, as a result of our acquisitions of our compounding pharmacies, and any additional pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to the transactions that are not incident to our operations.

For the Three and Six Months ended June 30, 2016 and 2015

There are no continuing operating sales and related cost of sales for the three and six months ended June 30, 2016 as we acquired our first pharmacy and recorded the transaction on June 30, 2016. Therefore, we plan to report revenue and pharmacy related operating costs during the third quarter of 2016. As a result of pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to these transactions.

Our total operating expenses for the three months ended June 30, 2016 pertaining to continuing operations were $1,679,986, respectively that were comprised primarily of expenses of $546,000 pertaining to shares issued for board and consulting services (noncash), $931,668 for shares and options issued to employees (noncash), $130,905 of management, financial advisory fees and accounting services and $114,276 of professional fees related to SEC and audit filings services and legal expense.

Our total operating expenses for the six months ended June 30, 2016 pertaining to continuing operations were $2,512,355, respectively that were comprised primarily of expenses of $1,133,500 pertaining to shares issued for board and consulting services (noncash), $943,634 for shares and options issued to employees (noncash), $229,235 of management, financial advisory fees and accounting services and $301,378 of professional fees related to SEC and audit filings services and legal expense.

There is $58,720 and $64,938, of interest expense for the three and six months ended June 30, 2016, respectively, pertaining to interest incurred for outstanding debentures that were not converted resulting from the spin-out, and the convertible promissory notes.

There was a loss on the conversion of payables into common shares for continuing operations that resulted in debt extinguishment expense of $190,000 for the three and six months ended June 30, 2016 resulting from legal expenses that were converted into shares.

There was a net loss for continuing operations of $1,928,706 for the three ended June 30, 2016 and $2,767,293 for the six months ended, resulting from the aforementioned operating expenses.

A comparison has not been provided for three and six months ended June 30, 2015 as the financial results for three and six months ended June 30, 2015 are reported as discontinued operations as disclosed in Note 5 to the consolidated financial statements.

Liquidity and Capital Resources

We have financed our operations through the sale of equity securities. As of June 30, 2016, we had a working capital deficit of $874,877. Our working capital deficit is attributable to the fact that we began implementing the Company’s business plan of acquiring pharmaceutical compounding businesses. We have completed our first acquisition and will begin to report revenue and related expenses the third quarter of 2016.

Net cash used in operating activities from continuing operations was $258,815 for the six months ended June 30, 2016 which primarily reflects our business development efforts that pertaining to acquiring a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals and the formation of our management team and board of directors.

Net cash provided by investing activities for the three and six months ended June 30, 2016 was approximately $10,201 which represents the cash that was received from acquisition of P3 Compounding of Georgia, LLC.

Net cash provided by financing activities for the six months ended June 30, 2016 was approximately $241,000 which represents the cash that was received from sale of common stock, issuance of a convertible note payable and proceeds from a short-term loan.

A comparison has not been provided for the six months ended June 30, 2015 as the financial results for six months ended June 30, 2015 are reported as discontinued operations as disclosed in Note 5 to the consolidated financial statements.

Specific details related to our financing activities are as follows:

2016 Private Placements

During the six months ended June 30, 2016, we raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. We incurred $9,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.

On March 18, 2016, we issued a 12% Convertible Promissory Note (the “Convertible Note”) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note, on the date thereof, we issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid us in cash the full principal amount of the Convertible Note. Upon issuance the lender was awarded 15,000 restricted common shares as an origination fee which will have piggy back registration rights.

On May 19, 2016, we issued a 10% Convertible Promissory Note (the “Convertible Note B”) in the principal amount of $100,000 to the Lender. Pursuant to the terms of the Convertible Note B, on the date thereof, we issued the Convertible Note B to the Lender and, as consideration therefor, the Lender paid us in cash the full principal amount of the Convertible Note B. Upon issuance the lender was awarded 66,666 warrants to purchase our common stock at an exercise price of $2.50 for a term of twenty-four months.

Short-term Loan

As a result of the acquisition of P3 Compounding of Georgia, LLC we had a short-term loan with a loan agency for a principal amount of $52,000 for the purchase of future sales and credit card receivables of P3. Under the terms of the receivable purchase agreement, we purchased an advance of $50,000 plus $2,000 for origination costs with a 10.5% daily interest rate to be repaid over 160 days at a repayment amount of $451.75 per day. Upon maturity of the loan the total repayment amount will be $72,280. As of June 30, 2016, the carrying value of this short term loan was $44,350. For the three and six months ended June 30, 2016, no interest expense related to this loan was recorded in our consolidated financial statements as the effective date of acquisition was the last day of the quarter.

Financial Advisors

We engaged the services of brokers and investment bankers to assist us with accessing our growth capital. In exchange, we will pay fees of up to 8% of the aggregate price upon closing any fundraising. Also, the advisors may be entitled to warrants to purchase shares of our common stock of up to 8% of the shares sold in the offering.

Plan of Operations

We are entering the Compounding Pharmacy Industry via a roll-up of existing compounding pharmacies consolidating fragmented market. The key elements of our strategy include:

	■	we intend to grow regionally, building regional distribution centers, expand sales and marketing with eventually with a national presence;
	■	we intend to acquire multiple libraries of compounding formulations in the process, recognizing that:
	■	some are tailored for local needs;
	■	some will have regional markets with expanded marketing;
	■	some can become nationally accepted, and further “productized” solutions;
	■	in all cases, we intend to drive the costs down when compared to alternatives from “big pharma”.

The human market and the vet market are both large and growing, share many of the same solutions, and are in need of lower cost solutions. We will focus on a balance between legitimate insurance related revenue streams and cash pay business. We believe the pharmacy industry, and especially compounding pharmacy, can easily be described as having multiple “flavors”. We believe the markets for both people and pets are both underserved:

	■	Some sell basic OTC medications and provide “delivery only”, and most users rely on insurance reimbursement for payment;
	■	Some are “value added resellers”, using OTC recognized medications, then repackaging, or using combinations, to personalize the product for the client. While vet based is a cash business, the human side is largely insurance reliant;
	■	Some are like “OEM manufacturers”, like a generic drug maker, starting with basic, non-productized materials, and creating both standard and fully customized “novel” formulations for specific maladies and needs. These are more often cash clients, and this approach is well accepted in the pet area, and becoming more accepted for people as alternatives to OTC, and for cash buyers seeking lower cost;
	■	We believe a mix of these can serve the need to drive costs down, and allow innovative approaches to improve patient results.

Recent Developments

On April 4, 2016 we entered into a non-binding letter of intent to acquire Cherokee Compounding Pharmacy in Holly Springs, Georgia, a suburb of Atlanta. The agreement calls for purchase consideration of approximately $450,000. Payment will be split between cash and the issuance of common stock. The final allocation of each of these will be determined prior to closing, which is expected to occur in third quarter 2016. The letter of intent is not a definitive agreement, and we expect to execute a definitive agreement at closing.

On April 11, 2016 the Board of Directors elected Mr. James Driscoll, age 54, to the Board of Directors. Mr. Driscoll received 100,000 shares of restricted common stock as compensation for his service on the Board, consistent with prior appointments by us.

On April 11, 2016, Dr. William Ross, age 70, advised us that he desired to resign from the Board of Directors, as he intends to retire from all business activities. There were no disagreements, or conflicts with the Board and Dr. Ross.

On May 20, 2016 we entered into a non-binding letter of intent to acquire Innovation Compounding, Inc. (“Innovation”) in Kennesaw, Georgia. We incurred $30,000 of expenses related to a fee for a “no-shop” provision, in addition to other customary expenses associated with the due diligence process. Management has determined not to pursue this acquisition further at this time.

On May 25, 2016 we announced that it has appointed Mr. Phillip Crone to its Board of Directors and accepted the resignation of Dr. Jeffrey Cosman, who has decided to commit all of his time and energy pursuing the continued development of Meridian Waste Solutions, Inc. (OTCQB: MRDN). There were no disagreements, or conflicts with the Board and Mr. Cosman.

On June 7, 2016, we announced that it has appointed Mr. James Driscoll as CEO. The former CEO Steve Keaveney has assumed the role of CFO.

On July 6, 2016, the Company appointed Gary Meyer to the newly created position of Chief Compliance Officer, providing oversight to its compounding pharmacy operations in the area of licensing, operational compliance and to interface with the appropriate regulatory bodies at the state and federal level. Mr. Meyer is 51 years old, and has over 25 years’ experience in the pharmacy area. He worked as a Pharmacist in Charge for CRC Pharmacy from August 2015 to July 2016, Physicians Rx Pharmacy from April 2015 to July 2015, Dunwoody Pharmacy from 1995 to February 2015, Concord Pharmacy from 1992 to 1995 and Kroger Pharmacy in 1992.

Mr. Meyer has a bachelor’s of Science in Pharmacy from The University of Georgia. Mr. Meyer holds a Georgia Board of Pharmacy license, is a Past Board Member of the Pharmacy Franchise & Owners Association, a member of National Community Pharmacists Association, Georgia Pharmacy Association, the International Academy of Compounding Pharmacists and the Professional Compounding Centers of America. He will report to James Driscoll.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This Item is not required for a Smaller Reporting Company.

ITEM 4. CONTROLS AND PROCEDURES.

As of the end of the period covered by this report (the “Evaluation Date”), we carried out an evaluation regarding the six months ended June 30, 2016, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer who is also serving as our Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon this evaluation, our management concluded that, as of the Evaluation Date, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed in the reports that are filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms and that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that the Company’s disclosure controls and procedures will detect or uncover every situation involving the failure of persons within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports.

The Company’s management is also responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. As of the Evaluation Date, no changes in the Company’s internal control over financial reporting occurred that have materially affected or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Our Annual Report on Form 10-K contains information regarding a material weakness in our internal control over financial reporting as of December 31, 2015 due to an inadequate segregation of duties resulting from our limited number of employees whom duties can be allocated.

During the second quarter of 2016, there were no changes that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. Legal Proceedings

In December 2015 we were named as Defendant in a suit from National Council for Science in the Environment (NCSE) seeking to collect $170,000 related to a services and consulting relationship dating back to 2009, a part of the legacy educational business, and not related to our ongoing pharmacy activities. We have filed a response and counterclaims including fraud claim. We believe our counterclaim for damages will far exceed the amounts they sought to recover. We intend to vigorously defend their claims. We have recorded a liability as of June 30, 2016 based on our best estimate of the probable exposure pertaining to the claim.

ITEM 1A. Risk Factors

We believe there are no changes that constitute material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on May 2, 2016.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

2016 Private Placements

During the six months ended June 30, 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. The Company incurred $9,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.

On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the “Convertible Note”) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note, on the date thereof, the Company issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note. Upon issuance the lender was awarded 15,000 restricted common shares as an origination fee which will have piggy back registration rights.

2015 Private Placements

The Company acquired 100% of the membership interests of Newco4pharmacy, LLC, a business aimed at creating a nationwide network of compounding pharmacies. The consideration paid was the issuance of a newly created Series X Preferred stock which was exchanged on December 31, 2015 for 10,000,000 shares of our common stock. The Company obtained approximately $106,900 in cash from Newco4pharmacy. Funds received resulted from a Newco4pharmacy membership interest sale prior to the transaction. As a result of this transaction the Company issued Founders shares of 3,488,900 to the CEO and Founder, Stephen Keaveney and 3,988,900 to individuals and entities that were instrumental in the formation of the N4P business. The Company also issued 455,000 shares to broker-dealers and 1,353,200 to other individuals for services performed in connection with the formation of the company.

August 2014 Convertible Debentures (Series C)

As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series C Convertible Debenture (the “Series C Debenture”) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured November 2015, and is convertible into the Company’s common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures. As of June 30, 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $19,950. For the three and six months ended June 30, 2016, interest expense related to the Debenture was $3,325 and $6,613, respectively.

November 2014 Convertible Debentures (Series D)

As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the “Series D Debenture”) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,333 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured November 2015, and is convertible into the Company’s common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures. As of June 30, 2016, the carrying value of the Series D Debenture was $11,334 and accrued interest expense of $2,267. For the three and six months ended June 30, 2016, interest expense related to the Debenture was $340 and $686, respectively.

All of the shares issued in the transactions described above were issued in private placement transactions and were exempt from registration under Section 4(2) of the Securities Act of 1933, as amended, as sales of securities not involving a public offering.

ITEM 3. Defaults upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures.

This Item is not applicable to our company’s operations.

ITEM 5. Other Information

None.

PART IV

Exhibit Number		Description
3.1		Certificate of Incorporation of Trunity Holdings, Inc. dated as of January 18, 2012 (incorporated herein by reference to Exhibit 10.1 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

3.2		Certificate of Ownership and Merger dated as of January 24, 2012, between Trunity Holdings, Inc. and Brain Tree International, Inc. (incorporated herein by reference to Exhibit 3.3 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

3.3		Certificate of Designation of Series X Preferred Stock of Trunity Holdings, Inc., dated as of December 9, 2015 (incorporated by reference to Exhibit 3.1 as part of the Company’s Form 8-K dated December 15, 2015 (Commission File No. 000-53601)

3.4		Certificate of Amendment to the Certificate of Incorporation of Trunity Holdings, Inc., dated as of December 24, 2015 (incorporated by reference to Exhibit 3.1(I) as part of the Company’s Form 8-K dated January 6, 2016 (Commission File No. 000-53601)

3.5		Bylaws of Trunity Holdings, Inc. (incorporated herein by reference to Exhibit 10.2 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

10.1		Spin-off and Asset Transfer Agreement dated as of December 31, 2015, by and among Trunity Holdings, Inc., Trunity, Inc., a Delaware corporation, and Trunity, Inc., a Florida corporation.(incorporated by reference to Exhibit 10.1 as part of the Company’s Form 8-K dated January 6, 2016 (Commission File No. 000-53601))

10.2		Securities Exchange Agreement dated as of December 9, 2015 by and among Trunity Holdings, Inc. and the Members of Newco4Pharmacy, LLC (incorporated by reference to Exhibit 10.1 as part of the Company’s Form 8-K dated December 15, 2015 (Commission File No. 000-53601))

10.3		Consulting Agreement dated as of December 1, 2015 by and between Trunity Holdings, Inc. and Stephen Keaveney (incorporated by reference to Exhibit 10.2 as part of the Company’s Form 8-K dated December 15, 2015 (Commission File No. 000-53601))

10.4		Securities Purchase Agreement dated as of November 5, 2014 by and between Trunity Holdings, Inc. and Peak One Opportunity Fund, L.P. (incorporated by reference to Exhibit 10.15 as part of the Company’s Form 10-Q for the quarter ending September 30, 2014 (Commission File No. 000-53601))

10.5		Trunity Holdings, Inc. Non-Qualified Stock Option Agreement dated as of December 13, 2013 by and between Arol Buntzman and Trunity Holdings, Inc. (incorporated by reference to Exhibit 10.14 as part of the Company’s Form 10-K for the year ending December 31, 2013 (Commission File No. 000-53601))

10.6		Memorandum of Understanding Regarding Trunity Holdings, Inc. and PIC Partners dated as of June 5, 2013 by and between Pan-African Investment Company and Trunity Holdings, Inc. (incorporated by reference to Exhibit 10.13 as part of the Company’s Form 10-K for the year ending December 31, 2013 (Commission File No. 000-53601))

10.7		Indemnification Agreement dated May 30, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit 10.12 filed as part of the Company’s Form 10-K for the year ended December 31, 2013 (Commission File No. 000-53601)).

10.8		Voting Agreement dated June 5, 2013 by and among Trunity Holdings, Inc., Terry Anderton, RRM Ventures, LLC, Aureus Investments, LLC and Pan-African Investment Company, LLC (incorporated by reference to Exhibit C as part of the Company’s Schedule 13D dated July 25, 2013 (Commission File No. 000-53601))

10.9		Voting Agreement dated May 30, 2013 by and among Trunity Holdings, Inc., Terry Anderton, RRM Ventures, LLC, Aureus Investments, LLC and Pan-African Investment Company, LLC (incorporated by reference to Exhibit 10.11 as part of the Company’s Form 10-K for the year ending December 31, 2013 (Commission File No. 000-53601))

10.10		Investors Rights Agreement dated May 30, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit 10.10 filed as part of the Company’s Form 10-K for the year ended December 31, 2013 (Commission File No. 000-53601)).

10.11		Investors Rights Agreement dated June 5, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit D filed as part of the Company’s Schedule 13D dated July 25, 2013 (Commission File No. 000-53601)).

10.12		Subscription Agreement dated May 28, 2013 between the Company and Pan African Investment Company (incorporated herein by reference to Exhibit 10.9 filed as part of the Company’s Form 10-K for the year ended December 31, 2013 (Commission File No. 000-53601)).

10.13		Form of Indemnification Agreement between Trunity and its Directors (incorporated herein by reference to Exhibit 10.8 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000- 53601)).

10.14		License Agreement dated as of March 20, 2013, between Trunity and Educom Ltd. (incorporated herein by reference to Exhibit 10.7 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.15		Share Purchase Agreement dated as of March 20, 2013, between Trunity and InnSoluTech LLP (incorporated herein by reference to Exhibit 10.6 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.16		Investment Project Contract dated as of March 20, 2013, among Trunity, InnSoluTech LLP and Educom Ltd. (incorporated herein by reference to Exhibit 10.5 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.17		Trunity Holdings, Inc. 2012 Employee, Director and Consultant Stock Option Plan (incorporated herein by reference to Exhibit 10.4 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

10.18		Agreement and Plan of Merger, dated as of January 24, 2012 by and among Trunity Holdings, Inc., Trunity Acquisitions Corp. and Trunity, Inc. (incorporated herein by reference to Exhibit 10.5 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

10.19		Stock Purchase Agreement between dated as of January 24, 2012 by and among George Norman, Donna Norman, Lane Clissold, Trunity Holdings, Inc. and Trunity, Inc. (incorporated herein by reference to Exhibit 10.3 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

10.20		Agreement and Plan of Merger, dated as of January 24, 2012 by and among Brain Tree International, Inc. and Trunity Holdings, Inc. (incorporated herein by reference to Exhibit 10.4 filed as part of the Company’s Form 8-K dated January 24, 2012 (Commission File No. 000-53601)).

14		Code of Ethics (incorporated herein by reference to Exhibit 14 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

21		Subsidiaries of the Company (incorporated herein by reference to Exhibit 21 filed as part of the Company’s Form 10-K for the year ended December 31, 2012 (Commission File No. 000-53601)).

31.1 *		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 *		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 *		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *		XBRL INSTANCE DOCUMENT

101.SCH *		XBRL TAXONOMY EXTENSION SCHEMA

101.CAL *		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

101.DEF *		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

101.LAB *		XBRL TAXONOMY EXTENSION LABEL LINKBASE

101.PRE *		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

* Filed herewith.

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRUE NATURE HOLDING, INC.

Dated: August 9, 2016	By:	/s/ Stephen Keaveney
		Stephen Keaveney Chief Financial Officer

	TRUE NATURE HOLDING, INC.

Dated: August 9, 2016	By:	/s/ James Driscoll
		James Driscoll Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature and Title		Date

/s/ Stephen Keaveney		August 9, 2016
Stephen Keaveney
Chief Financial Officer, and Chairman of the Board

/s/ Phillip Crone		August 9, 2016
Phillip Crone
Director

/s/ James Driscoll		August 9, 2016
James Driscoll
Director

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, James Driscoll, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of True Nature Holding, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	TRUE NATURE HOLDING, INC.

Dated: August 9, 2016	By:	/s/ James Driscoll
		James Driscoll Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Stephen Keaveney, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of True Nature Holding, Inc.;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	TRUE NATURE HOLDING, INC.

Dated: August 9, 2016	By:	/s/ Stephen Keaveney
		Stephen Keaveney Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of True Nature Holding, Inc. (the “Company”) for the quarter year ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen Keaveney, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	TRUE NATURE HOLDING, INC.

Dated: August 9, 2016	By:	/s/ James Driscoll
		James Driscoll Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certifications are accompanying the Company’s Form 10-Q solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of True Nature Holding, Inc. (the “Company”) for the quarter year ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen Keaveney, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	TRUE NATURE HOLDING, INC.

Dated: August 9, 2016	By:	/s/ Stephen Keaveney
		Stephen Keaveney Chief Financial Officer

EX-101.INS 6 tntyob-20160630.xml XBRL INSTANCE FILE 0000802257 2016-01-01 2016-06-30 0000802257 2016-08-08 0000802257 2015-12-31 0000802257 2016-03-31 0000802257 tntyob:N2009EmployeeDirectorAndConsultantStockOptionPlanThe2009PlanMember 2015-01-01 2015-12-31 0000802257 tntyob:N2012EmployeeDirectorAndConsultantStockOptionPlanThe2012PlanMember 2015-01-01 2015-12-31 0000802257 2016-01-01 2016-01-31 0000802257 tntyob:StephenKeaveneyMember 2016-01-01 2016-06-30 0000802257 tntyob:ShareholderMember 2016-01-01 2016-06-30 0000802257 us-gaap:ChiefExecutiveOfficerMember 2014-12-31 0000802257 tntyob:N2009EmployeeDirectorAndConsultantStockOptionPlanThe2009PlanMember 2015-12-31 0000802257 tntyob:N2012EmployeeDirectorAndConsultantStockOptionPlanThe2012PlanMember 2015-12-31 0000802257 2015-12-01 2015-12-16 0000802257 us-gaap:CommonStockMember 2015-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000802257 us-gaap:RetainedEarningsMember 2015-12-31 0000802257 2014-12-31 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-03-18 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2015-12-31 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2015-12-31 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2016-06-30 0000802257 tntyob:ConvertiblePromissoryBNoteMember 2016-03-01 2016-03-18 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2015-01-01 2015-12-31 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2015-01-01 2015-12-31 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-03-31 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2016-06-30 0000802257 us-gaap:RestrictedStockMember tntyob:BoardMember 2016-03-31 0000802257 us-gaap:RestrictedStockMember us-gaap:MinimumMember 2016-03-31 0000802257 us-gaap:RestrictedStockMember us-gaap:MaximumMember 2016-03-31 0000802257 us-gaap:RestrictedStockMember tntyob:BoardMember 2016-01-01 2016-06-30 0000802257 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2016-01-01 2016-03-31 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2016-01-01 2016-06-30 0000802257 us-gaap:WarrantMember 2015-01-01 2015-06-30 0000802257 us-gaap:WarrantMember 2016-01-01 2016-06-30 0000802257 us-gaap:OptionMember 2016-01-01 2016-06-30 0000802257 us-gaap:OptionMember 2015-01-01 2015-06-30 0000802257 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-06-30 0000802257 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-06-30 0000802257 tntyob:WilliamLRossAndJeffreyCosmanMember 2016-01-01 2016-01-25 0000802257 2016-06-30 0000802257 2016-04-01 2016-06-30 0000802257 2015-04-01 2015-06-30 0000802257 2015-01-01 2015-06-30 0000802257 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0000802257 us-gaap:CommonStockMember 2016-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000802257 us-gaap:RetainedEarningsMember 2016-01-01 2016-06-30 0000802257 us-gaap:RetainedEarningsMember 2016-06-30 0000802257 us-gaap:WarrantMember 2016-06-30 0000802257 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember 2016-07-22 2016-08-02 0000802257 us-gaap:WarrantMember 2015-12-31 0000802257 tntyob:N2009EmployeeDirectorAndConsultantStockOptionPlanThe2009PlanMember 2016-06-30 0000802257 tntyob:N2012EmployeeDirectorAndConsultantStockOptionPlanThe2012PlanMember 2016-06-30 0000802257 tntyob:November2014ConvertibleDebenturesSeriesDMember 2016-04-01 2016-06-30 0000802257 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-06-30 0000802257 tntyob:StephenKeaveneyMember 2016-04-01 2016-06-30 0000802257 tntyob:JamesDriscollMember 2016-01-01 2016-06-30 0000802257 tntyob:ShareholderMember 2016-04-01 2016-06-30 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-04-01 2016-06-30 0000802257 tntyob:ConvertiblePromissoryNoteMember 2016-01-01 2016-06-30 0000802257 us-gaap:RestrictedStockMember tntyob:VpOfCorporateDevelopmentMember 2016-06-30 0000802257 us-gaap:RestrictedStockMember tntyob:VpOfCorporateDevelopmentMember 2016-01-01 2016-06-30 0000802257 us-gaap:RestrictedStockMember tntyob:P3AConvertibleNoteMember 2016-06-30 0000802257 us-gaap:RestrictedStockMember tntyob:P3AConvertibleNoteMember 2016-01-01 2016-06-30 0000802257 tntyob:ConvertiblePromissoryBNoteMember 2016-05-01 2016-05-19 0000802257 tntyob:ConvertiblePromissoryBNoteMember 2016-05-19 0000802257 tntyob:ConvertiblePromissoryBNoteMember 2016-04-01 2016-06-30 0000802257 tntyob:ConvertiblePromissoryNoteBMember 2016-01-01 2016-06-30 0000802257 tntyob:ConvertiblePromissoryNoteBMember 2016-06-30 0000802257 tntyob:P3CompoundingOfGeorgiaMember 2016-01-01 2016-06-30 0000802257 tntyob:P3CompoundingOfGeorgiaMember 2016-06-30 0000802257 tntyob:JimDriscollMember 2016-06-01 0000802257 tntyob:JimDriscollMember 2016-05-01 2016-06-01 0000802257 2016-04-04 0000802257 2016-05-20 0000802257 2015-06-30 0000802257 tntyob:PhillipCroneMember 2016-05-01 2016-05-25 0000802257 us-gaap:SubsequentEventMember us-gaap:DirectorMember 2016-07-01 2016-07-06 0000802257 tntyob:ConvertiblePromissoryNoteAMember 2016-06-30 0000802257 tntyob:August2014ConvertibleDebenturesSeriesCMember 2016-01-01 2016-06-30 0000802257 tntyob:JimDriscollMember 2016-01-01 2016-06-30 0000802257 tntyob:JimDriscollMember 2016-04-01 2016-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0000802257 10-Q 2016-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2016

10000000

500000000

15000

340000

16363

150

16213

425000

-699729

-1322199

-685647 -1309392

1 for 101

66458

185137

27894

90023

38564

95114

419546

866511

-380982

-771397

14082

12807

10000

18645

26000

12500

1395

67879

24753

1067879

142653

78462

1000000

66666

-2475

354911

142653

21.40

3.00

17.42

29.55

1.75

2.50

50.50

4.99

17.42

P7Y2M1D

P3Y5M5D

P5Y2M19D P2Y6M

P4Y11M12D

P2Y6M

18152 74257

3610

45673

Stock options typically vest over a three-year period and have a life of ten years from the date granted.

Stock options typically vest over a three year period and have a life of ten years from the date granted.

780

1041377

1040793

177270

0.12 True Nature Holding, Inc.

318747

550802

186950 381649 232596 484862

45185

906415

-519688

117650

3917

-641255

-156880

131750

3119918

-3408548

-641255

-3408548

3917

3119918

117650

131750

564873

1063295

564873

1063295

122167

224962

13325

46569

14918 24600

414463

600647

45185

906415

45185

188418

17000

4250

30179

12368961

12687478

545386

543996

-0.22

-0.15

-1.28

-2.43

-1.28

-2.43

-0.22

-0.15

-2767293

-1928706

-685647

-1309392

-2767293

-1928706

-699729

-1322199

-2767293

14082

12807

-2767293

-1928706

-2767293

-1928706

64938

58720

-2512355

-1679986

2512355

1679986

2512355

1679986

11765000

13175000

120000 51000 1200 49800 533804 533804

508634

160000

-258815

42926

150762

-7527

-406500 -727000

40129

508634

496668

-2767293

-1322199

0.01

11765000

P1Y11M1D

Note 1  Description of Business   True Nature Holding, Inc. is executing on a business plan to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals. The Company completed its first acquisition of P3 Compounding in June 2016 and is pursuing a series of compounding pharmacy acquisitions.   True Nature Holding, Inc. (the Company), previously known as Trunity Holdings, Inc., became a publicly-traded company through a reverse merger with Brain Tree International, Inc., a Utah corporation (BTI). Trunity Holdings, Inc. was the parent company of the prior educational business, named Trunity, Inc., which was formed on July 28, 2009 through the acquisition of certain intellectual property by its three founders. On December 31, 2015, the Company completed the restructuring and spin-out of the educational business.

Note 4  Financial Condition and Going Concern   As of June 30, 2016, the Company had cash on hand of $20,571 and current liabilities of $1,063,295 and has incurred a loss from operations. True Nature Holdings principal operations is the acquisition of compounding pharmacy companies. The Companys activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.   As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern. The Companys continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered into discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists.   The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

Note 5 Spin-Out and Discontinued Operations   On December 31, 2015, the Company completed the restructuring and spin-out of its software educational business, resulting in True Nature Holding, Inc. becoming purely focused on acquiring a series of compounding pharmacy businesses, largely direct to consumers, doctors and veterinary professionals. The results of the operations associated with the spin-out company and Trunity Holdings, Inc., qualifies as discontinued operations as of and for the three and six month periods ended June 30, 2015.   The results of operations associated with discontinued operations were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: center"></td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center">Three Months Ended </td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"></td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30, 2015</td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30, 2015</td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 66%; font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Net Sales</td><td style="width: 3%; font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: normal 8pt Times New Roman, Times, Serif; text-align: right">66,458</td><td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 3%; font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: normal 8pt Times New Roman, Times, Serif; text-align: right">185,137</td><td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Cost of sales</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">27,894</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">90,023</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Gross Profit</td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">38,564</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">95,114</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Operating Expenses:</td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Research and development</td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">186,950</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">381,649</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Selling, general and administrative</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">232,596</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">484,862</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-bottom: 1pt">Total operating expenses</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">419,546</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">866,511</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Operating Loss from Discontinued Operations</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(380,982</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(771,397</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Other Expense:</td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Interest expense, net</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(318,747</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(550,802</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss from Discontinued Operations</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(699,729</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(1,322,199</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Other Comprehensive Loss Net of Tax:</td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">14,082</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">12,807</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Comprehensive Loss from Discontinued Operations</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(685,647</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(1,309,392</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>   Our educational business was fully disposed of in December 2015.  As a result, there were no assets or liabilities of discontinued operations as of December 31, 2015 or in subsequent periods.

Note 8 Debt   Convertible Promissory Notes   On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the Convertible Note A) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note A, on the date thereof, the Company issued the Convertible Note A to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note A. Upon issuance the lender was awarded 15,000 restricted common shares as an origination fee which have certain registration rights.   Pursuant to the terms of the Convertible Note A, the Company is obligated to pay monthly installments of not less than $1,000 the first of each month commencing the month following the execution of this note until its full maturity on September 16, 2016 at which time the Company is obligated to repay the full principal amount of the Convertible Note A. The Convertible Note A is convertible by the holder at any time into shares of the Companys common stock at an effective conversion price of $1.00 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note A to the shares and the note based on relative fair values, and the amount allocated to the shares of $16,364 was recorded as a discount against the note, with an offsetting entry to additional paid-in capital. The beneficial conversion feature of $16,364 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of June 30, 2016, the carrying value of this Convertible Note A was $45,872 and accrued interest expense of $1,080. For the three and six months ended June 30, 2016, debt discount amortization related to the Convertible Note A was $16,274 and $18,599, respectively and its related interest expense was$1,820 and $2,080, respectively.   On May 19, 2016, the Company issued a 10% Convertible Promissory Note (the Convertible Note B) in the principal amount of $100,000 to the Lender. Pursuant to the terms of the Convertible Note B, on the date thereof, the Company issued the Convertible Note B to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note B. Upon issuance the lender was awarded 66,666 warrants to purchase common stock of the Companyat an exercise price of $2.50 for a term of twenty-four months.   Pursuant to the terms of the Convertible Note B, the Company is obligated to repay the full principal amount of the Convertible Note B with any unpaid interest upon the date of maturity, June 19, 2017. The Convertible Note Bis convertible by the holder at any time into shares of the Companys common stock at an effective conversion price of $1.50 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note B to the shares and the note based on relative fair values, and the amount allocated to the shares of $39,887 was recorded as a discount against the note, with an offsetting entry to additional paid-in capital. The beneficial conversion feature of $52,553 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of June 30, 2016, the carrying value of this Convertible Note B was $29,090and accrued interest expense of $1,167.For the three and six months ended June 30, 2016, debt discount amortization related to the Convertible Note Bwas $21,530 and its related interest expense was $1,167.   Short-term Loan   As a result of the acquisition of P3 Compounding of Georgia, LLC the Company had a short-term loanwith a loan agency for a principal amount of $52,000 for the purchase of future sales and credit card receivables of P3. Under the terms of the receivable purchase agreement, the Company purchased an advance of $50,000 plus $2,000 for origination costs with a 10.5% daily interest rate to be repaid over 160 days at a repayment amount of $451.75 per day. Upon maturity of the loan the total repayment amount will be $72,280.As of June 30, 2016, the carrying value of this short term loan was $44,350. For the three and six months ended June 30, 2016, no interest expense related to this loan was recorded in the Companys consolidated financial statements as the effective date of acquisition was the last day of the quarter.   August 2014 Convertible Debentures (Series C)   In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion; however, one debenture holder that was issued a Series C Convertible Debenture (the Series C Debenture) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured on October 31, 2015, and is convertible into the Companys common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of June 30, 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $19,950. For the three and six months ended June 30, 2016, interest expense related to the Debenture was $3,325 and $6,613, respectively.   November 2014 Convertible Debentures (Series D)   In fiscal 2015, all debentures issued by Trunity Holdings, Inc. to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the Series D Debenture) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,334 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured on October 31, 2015, and is convertible into the Companys common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business in fiscal 2014 allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed in fiscal 2014 upon execution of the new debentures. As of June 30, 2016, the carrying value of the Series D Debenture was $11,334 and accrued interest expense of $2,267. For the three and six months ended June 30, 2016, interest expense related to the Debenture was $340 and $686, respectively.

Note 9 Stockholders Deficit   Sale of Common Stock During the six months ended June 30, 2016, the Company raised gross proceeds of $60,000 through the sale of 120,000 shares of common stock to accredited investors in private placement transactions at a price of $0.50 per share. The Company incurred $9,000 of securities issuance costs representing commissions paid to broker-dealers who assisted with these transactions.   Shares for Consulting Services and Board Members During the six months ended June 30, 2016, in connection with services rendered, the Company issued 410,000 restricted shares of the Companys common stock at values of $2.90, $1.45 and $0.90 per share in exchange for financial consulting and legal services conducted on behalf of the Company. In addition, in connection with services rendered for board members, the Company issued 400,000 restricted shares of the Companys common stock at values of $1.45, $2.02 and $2.35 per share in exchange for their services conducted on behalf of the Company. The issuance of these shares were recorded at the fair value of the shares at the date of issuance.   Shares for Employee During the six months ended June 30, 2016, in connection with employment contract, the Company issued 125,000 restricted shares of the Companys common stock at a value of $3.48 per share in exchange for Casey Gaetano becoming the Companys VP of Corporate Development.   Shares issued for convertible note payable As discussed in Note 8, during the six months ended June 30, 2016, in connection with conversion of a six-month convertible promissory note, the Company issued 15,000 shares of the Companys common stock with a fair value of $16,363 that was allocated based on the relative fair value of the note and associated shares.   Debt beneficial conversion feature for convertible note payable During the six months ended June 30, 2016, the Company raised gross proceeds of $160,000 pursuant to two Convertible Notes Payable (Notes) that allocated the face value of the Note to the shares and debt based on their relative fair values and, resulted in the recording of beneficial conversion features totaling $108,804 as a discount against the Notes, with an offsetting entry to additional paid-in capital. The discount is being amortized into interest expense over the term of the Notes.   	Shares issued for convertible note payable of acquisition of P3 Compounding of Georgia, LLC- As part of the consideration for the acquisition of P3 a convertible note in the amount of $425,000 was converted into common stock of the Company at price per share of $1.25 resulting in the issuance of 340,000 shares of common stock.

Note 10 Stock-Based Compensation   The Company has two Employee, Director and Consultant Stock Option Plans that were not terminated as a result of the fiscal 2015 restructuring of the Company and spin-out and have continued as part of the operations as detailed below.   In fiscal 2015, the option pool pertaining to the 2009 Employee, Director and Consultant Stock Option Plan (the 2009 Plan) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized option pool of 18,152. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of June 30, 2016 there were 3,610 shares available for future awards under this plan.   In fiscal 2015, the option pool pertaining to the 2012 Employee, Director and Consultant Stock Option Plan (the 2012 Plan) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized options pool of 74,257. Stock options typically vest over a three year period and have a life of ten years from the date granted. As of June 30, 2016, there were 45,673 shares available for future awards under this plan.   In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of spin-out Companyin fiscal 2014. These options issued are outside of the 2009 and 2012 Plans.    On June 1, 2016Jim Driscoll was granted for his position as Chief Executive Officer(CEO) of the Company options to purchase up to 1,000,000 shares of Common Stock outside ofthe Companys 2009 and 2012 stock option plans (the Option Agreement). These options covered 250,000 shares at an exerciseprice of $1.00 per share to be granted immediately and three additional tranches of 250,000 shares each at an exercise price of $1.50, $2.00 and $2.50 per share,respectively. The remaining three tranches will vest equally over the next three years with the first fully vesting on May 31, 2017 through May 31, 2019. The term of the options will be for a period of five years and may be exercised at any time as to the vested shares.   During the three and six months ended June 30, 2016, the Company recorded stock compensation expense related to the options granted to Mr. Driscoll of $496,668 and has unrecognized stock expense of $1,040,793 to be recorded over the vesting period. The grant-date fair value of options was estimated using the Black-Scholes option pricing model. The per share weighted average fairvalue of stock options granted for Mr. Driscoll wasa range of $1.35-$1.76and was determined using the following assumptions: expected pricevolatility is 80.39%, risk-free interest rate of 1.39%, zero expected dividend yield, and 4.0 years expected life of options. Theexpected term of options granted is based on the simplified method in accordance with Securities and Exchange CommissionStaff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. TheCompany makes assumptions with respect to expected stock price volatility based on the average historical volatility of peerswith similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturitiessimilar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day.    As of June 30, 2016, unrecognized stock compensation expense related to unvested stock options under all Plans was $1,041, 377. This expense is expected to be recognized over the remaining weighted average vesting periods of the outstanding options of 1.92 years. Total stock compensation expense recorded to selling, general and administrative expenses on the consolidated statements of operations and comprehensive for the six month period ending June 30, 2016 related to the all Plans and options that vested during the period was $508,634.   A summary of options issued, exercised and cancelled are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; font: 8pt Times New Roman, Times, Serif">      </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Shares</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted- Average Exercise Price ($)</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted- Average Remaining Contractual Term</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Aggregate Intrinsic Value ($)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 39%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">67,879</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">21.40</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">7.17</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif"></td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">1,000,000</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">1.75</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">5.00</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Cancelled</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">1,067,879</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">3.00</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">5.22</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Exercisable at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">354,911</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">4.99</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">4.95</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> </table>

Note 11 Warrants to Purchase Common Stock   Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized.All warrants outstanding as of June 30, 2016 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Shares</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted- Average Exercise Price ($)</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted-Average Remaining Contractual Term</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 48%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 13%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">78,462</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="width: 13%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">29.55</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 13%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">3.43</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">66,666</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">2.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">2.00</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Expired</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">(2,475</td> <td style="font: 8pt/107% Times New Roman, Times, Serif">) </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">50.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">142,653</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">17.42</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">2.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Exercisable at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">142,653</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">17.42</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">2.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> </table>

Note 12 Commitments and Contingencies   Legal   National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No.. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division.   This action was filed on December 16, 2015 by the National Council for Science and the Environment, Inc. (NCSE) in the state court in the District of Columbia against Trunity Holdings, Inc. (Trunity) and alleges claims for Breach of Contract. Acknowledgement of Indebtedness and Settlement Agreement and Quantum Meruit arising out of an agreement entered into between NCSE and Trunity in 2014. The Complaint seeks damages in the amount of $177,270, inclusive of attorneys fees, costs and accrued interest, continuing interest in the amount of 12% per annum and attorneys fees and costs of collection relating to the case. The Company in its answer on January 27, 2016, denied the material allegations made by NCSE, asserted a number of affirmative defenses and filed a counterclaim alleging claims for fraud, negligent misrepresentation, breach of fiduciary duty, breach of contract and unjust enrichment. In its counterclaim, the Company will seek actual and compensatory damages against NCSE that it believes exceed the amount sought by NCSE on its claims, pre-judgment interest, punitive damages and all costs and expenses, including attorneys fees, incurred by the Company in bringing its claims against NCSE.   On February 19, 2016, NCSE filed a motion to dismiss the counterclaim, and the Company has filed its brief in the opposition to that motion. A hearing is scheduled in 2016 on the motion. No discovery has been conducted by the parties yet, and no trial date has been set by the court. We have recorded a liability as of June 30, 2016 based on our best estimate of the probable exposure pertaining to the claim.

Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Companys financial position at June 30, 2016, the results of operations for the three months and six months ended June 30, 2016 and 2015, and cash flows for the three months and six months ended June 30, 2016 and 2015. The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Companys audited consolidated financial statements and managements discussion and analysis included in the Companys annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 5 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.

Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

The results of operations associated with discontinued operations were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: center"></td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center">Three Months Ended </td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"></td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30, 2015</td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> </td><td nowrap="nowrap" style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30, 2015</td><td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 66%; font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Net Sales</td><td style="width: 3%; font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: normal 8pt Times New Roman, Times, Serif; text-align: right">66,458</td><td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 3%; font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 12%; font: normal 8pt Times New Roman, Times, Serif; text-align: right">185,137</td><td style="width: 1%; font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Cost of sales</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">27,894</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">90,023</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Gross Profit</td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">38,564</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">95,114</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Operating Expenses:</td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Research and development</td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">186,950</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right">381,649</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Selling, general and administrative</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">232,596</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">484,862</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-bottom: 1pt">Total operating expenses</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">419,546</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">866,511</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Operating Loss from Discontinued Operations</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(380,982</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(771,397</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Other Expense:</td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Interest expense, net</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(318,747</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(550,802</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: italic 8pt Times New Roman, Times, Serif"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss from Discontinued Operations</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(699,729</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">(1,322,199</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left">Other Comprehensive Loss Net of Tax:</td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif"> </td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: italic 8pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">14,082</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"> </td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">12,807</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: normal bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Comprehensive Loss from Discontinued Operations</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(685,647</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: normal 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double">$</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double">(1,309,392</td><td style="font: normal 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>

A summary of options issued, exercised and cancelled are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; font: 8pt Times New Roman, Times, Serif">      </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Shares</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted- Average Exercise Price ($)</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted- Average Remaining Contractual Term</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" nowrap="nowrap" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Aggregate Intrinsic Value ($)</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 39%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">67,879</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">21.40</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">7.17</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 12%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif"></td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">1,000,000</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">1.75</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">5.00</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Cancelled</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">1,067,879</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">3.00</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">5.22</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Exercisable at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">354,911</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">4.99</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">4.95</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr></table>

A summary of warrants issued, exercised and expired are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td colspan="2" style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Shares</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted- Average Exercise Price ($)</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td colspan="3" style="text-align: center; font: 8pt/107% Times New Roman, Times, Serif">Weighted-Average Remaining Contractual Term</td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 48%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at December 31, 2015</td> <td style="width: 1%; padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 13%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">78,462</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="width: 13%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">29.55</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 2%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="width: 13%; text-align: right; font: 8pt/107% Times New Roman, Times, Serif">3.43</td> <td style="width: 1%; font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Granted</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">66,666</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">2.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif">2.00</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Expired</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">(2,475</td> <td style="font: 8pt/107% Times New Roman, Times, Serif">) </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">50.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 8pt/107% Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Outstanding at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">142,653</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">17.42</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">2.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif">Exercisable at June 30, 2016</td> <td style="padding-left: 7.5pt; text-indent: -7.5pt; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">142,653</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">17.42</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 8pt/107% Times New Roman, Times, Serif; text-align: right">2.50</td> <td style="font: 8pt/107% Times New Roman, Times, Serif"> </td></tr> </table>

60000

52000

16364 10000 100000

15000

39887

0.12

0.10

0.105

2016-09-16

2015-10-31

2017-06-19

1.00

16.67

20.20

1.50

495

4950

20.20

P5Y P5Y 11334 110833 11334 29598 110833 29090 44350 45872

2267

260

19950

1167

1080

16364

16274

18599

52553

21530

1167

1000

0.50

1.45

0.90

1.45

0.50

3.48

1.25

6000

9000

400000

410000

125000

108804

120000

60000

3325

686

340

1820

2080

6613

50000

44350

7500

77640

142652

1067879

67483

135037

316721

100000 100000

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments.    The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of June 30, 2016, the Company had 142,652warrants, 1,067,879 options, 135,037 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of June 30, 2015, the Company had 77,640 warrants, 67,483 options, 316,721 potential shares which may be issued resulting from the provisions of convertible notes, respectively.

Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements.   In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective for annual periods beginning on or after December 15, 2016, including interim periods within those annual periods. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.   In August 2014, the FASB issued new accounting guidance which defines managements responsibility to assess an entitys ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.   In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Companys consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Companys cash flows.      In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

P5Y P2Y 2019-12-31

P7Y

151273

26000

111668

5294

151273

561430

727000 4000 723000 400000 406500 4100 402400 410000 261800 3400 258400 340000 435000 1250 433750 125000 -435000 50000 1000000

250000

1.00

0.8039

0.0139

0.00

P4Y

450000

30000

51000

241000

-239974

-72983

314838

1881

-7614

28185

14119

20571

16000

575167

274122

-10201

10201

30000

35422

314941 589350 561430 261800 45953

10201

26000

111668

20706

5294

151273

325142

35422

289720

851150

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date based on a fair value acquisition price of $876,150 pertaining to the consideration provided.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 80%; background-color: white; font: 8pt Times New Roman, Times, Serif">Cash and cash equivalents</td> <td style="width: 3%; background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; background-color: white; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 15%; text-align: right; font: 8pt Times New Roman, Times, Serif">10,201</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Accounts receivable</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">26,000</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Inventories</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">111,668</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Other current assets</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">20,706</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Furniture and equipment</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">5,294</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Customer list</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">151,273</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif">Total identifiable assets acquired</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">325,142</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Accounts payable and accrued expenses</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">35,422</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif">Total liabilities assumed</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">35,422</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif">Total identifiable assets less liabilities assumed</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">289,720</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Goodwill</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">561,430</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net assets acquired</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">851,150</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>

The following table sets forth the components of identified intangible assets associated with the P3 Acquisition and their estimated useful lives.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Fair Value</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 8pt Times New Roman, Times, Serif">Customer relationships</td> <td style="width: 1%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 14%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">151,273</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif">7 years</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">151,273</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table>

Accounts Receivable -The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Accounts receivable are stated at the invoiced amount and are unsecured and require no collateral. Charges to bad debt are based on both historical write-offs and specifically identified receivables.

Business Combinations -The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts; anddiscount rates utilized in valuation estimates.   Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.

Goodwill and Intangible Assets - Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed.  The Company accounts for goodwill and intangibles under ASC Topic 350, Intangibles Goodwill and Other, which does not permit amortization, but requires the Company to test goodwill and other indefinite-lived assets for impairment annually or whenever events or circumstances indicate impairment may exist.

10000 10000

Note 2 Summary of Significant Accounting Policies   Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Companys financial position at June 30, 2016, the results of operations for the three months and six months ended June 30, 2016 and 2015, and cash flows for the three months and six months ended June 30, 2016 and 2015. The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Companys audited consolidated financial statements and managements discussion and analysis included in the Companys annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 5 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.   Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.   Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments.    The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of June 30, 2016, the Company had 142,652 warrants, 1,067,879 options, 135,037 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of June 30, 2015, the Company had 77,640 warrants, 67,483 options, 316,721 potential shares which may be issued resulting from the provisions of convertible notes, respectively.   Accounts Receivable -The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Accounts receivable are stated at the invoiced amount and are unsecured and require no collateral. Charges to bad debt are based on both historical write-offs and specifically identified receivables.   Inventories -Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. In addition, the Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.   Property and Equipment, net - Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed generally on a straight-line basis over the estimated useful lives of the assets. The cost of leasehold improvements are amortized either over the life of the improvement or the lease term, whichever is shorter. Significant improvements are capitalized and disposed or replaced property is written off. Maintenance and repairs are charged to expense in the period they are incurred. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts, and any gain or loss is included in earnings.   Business Combinations -The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts; anddiscount rates utilized in valuation estimates.   Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.   Goodwill and Intangible Assets - Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed.  The Company accounts for goodwill and intangibles under ASC Topic 350, Intangibles Goodwill and Other, which does not permit amortization, but requires the Company to test goodwill and other indefinite-lived assets for impairment annually or whenever events or circumstances indicate impairment may exist.   Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements.   In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective for annual periods beginning on or after December 15, 2016, including interim periods within those annual periods. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.   In August 2014, the FASB issued new accounting guidance which defines managements responsibility to assess an entitys ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.   In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Companys consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Companys cash flows.     In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

Note 3 Recent Developments   On April 4, 2016 the Company entered into a non-binding letter of intent to acquire Cherokee Compounding Pharmacy in Holly Springs, Georgia, a suburb of Atlanta. The agreement calls for purchase consideration of approximately $450,000. Payment will be split between cash and the issuance of common stock. The final allocation of each of these will be determined prior to closing, which is expected to occur in third quarter 2016. The letter of intent is not a definitive agreement, and the Company expects to execute a definitive agreement at closing.   On May 20, 2016 the Company entered into a non-binding letter of intent to acquire Innovation Compounding, Inc. (Innovation) in Kennesaw, Georgia. The Company incurred $30,000 of expenses related to a fee for a no-shop provision, in addition to other customary expenses associated with the due diligence process. Management has determined not to pursue this acquisition further at this time.

Note 6 - Acquisition   On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC,(P3).P3 received Georgia Board of Pharmacy approval for the transaction at the end of June 2016 and the transaction closed effective June 30, 2016. P3 is a full service compounding pharmacy with both sterile and non-sterile expertise headquarter in Atlanta, Georgia. The medicines that P3 compounds include bio-identical hormone replacement therapy, transdermal pain creams, wellness compounding, individualized and prescriptions.The transaction included the acquisition of identifiable assets, customer listings and intellectual properties included in the P3s library of specialized formulations.   As a result of the acquisition, P3 is now a wholly owned subsidiary of the Company. The acquisition of P3 permits the Company to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions through P3 and introduces the Company to new geographic and compounded formulation markets.   The transaction has been accounted for as a business combination and recorded as of June 30, 2016, therefore no revenues or net income have been included in the Companys consolidated financial statements for second quarter 2016.   The fair value of the consideration paid pertaining to the acquisition of P3 was $851,150. Consideration for the transaction was structured as follows:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 13.5pt; font: 8pt Times New Roman, Times, Serif"></td><td style="width: 18pt; font: 8pt Times New Roman, Times, Serif"></td><td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">An interest-free note for $150,000 with no interest to be paid in full via wire transfer on the maturity date of August 16, 2016;</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 13.5pt; font: 8pt Times New Roman, Times, Serif"></td><td style="width: 18pt; font: 8pt Times New Roman, Times, Serif">▪</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">$425,000 convertible note with a term of 12 months and a 6% interest rate, with the first installment due June 1, 2016, and convertible into common stock of True Nature at a rate of $1.25 per share (which is 340,000 shares of common stock), less a short-term financing for $14,350 that the Company provided to Integrity for working capital purposes;</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 13.5pt; font: 8pt Times New Roman, Times, Serif"></td><td style="width: 18pt; font: 8pt Times New Roman, Times, Serif">▪</td><td style="text-align: justify; font: 8pt Times New Roman, Times, Serif">A $425,000 convertible note with no interest, which automatically converted 340,000 shares of common stock with a fair value of $261,800 based on the closing price of the True Natures common stock on June 30, 2016.</td></tr></table>    The notes issued in conjunction with the purchase and the intellectual properties may be converted into restricted common stock at a rate of $1.25 per share. The purchase includes all payables, receivables, cash on hand, inventory and all assets used in the operation of the business.   In addition, Mr. Casey Gaetano, a former owner of P3, received an employment contract with True Nature for 3 years as VP of Corporate Development, at an annual salary of $125,000, plus normal benefits commensurate with other executives in the Company of equal stature. He also receive in second quarter 2016, 125,000 shares of restricted at a value of $3.48 per share in exchange for becoming the Companys VP of Corporate Development.   Allocation of Consideration Transferred   The identifiable assets acquired and liabilities assumed were recognized and measured as of the acquisition date based on their estimated fair values as of June 30, 2016. The excess of the acquisition date fair value of consideration transferred over the estimated fair value of the net tangible assets and intangible assets acquired was recorded as goodwill.    The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date based on a fair value acquisition price of $851,150 pertaining to the consideration provided.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="width: 80%; background-color: white; font: 8pt Times New Roman, Times, Serif">Cash and cash equivalents</td> <td style="width: 1%; background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; background-color: white; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 17%; text-align: right; font: 8pt Times New Roman, Times, Serif">10,201</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Accounts receivable</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">26,000</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Inventories</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">111,668</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Other current assets</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">20,706</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif">Furniture and equipment</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">5,294</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Customer list</td> <td style="background-color: white; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="background-color: white; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">151,273</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif">Total identifiable assets acquired</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">325,142</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Accounts payable and accrued expenses</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">35,422</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif">Total liabilities assumed</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">35,422</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif">Total identifiable assets less liabilities assumed</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif">289,720</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Goodwill</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">561,430</td> <td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net assets acquired</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">851,150</td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td></tr> </table>   The fair value of the transaction and related purchase price allocation was based on a third-party valuation obtained by the Company.   Intangible Assets-Customer Relationships   In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of the acquired assets, analyses of historical financial performance of P3 and estimates of future performance of P3. The fair values of the identified intangible assets related to P3s customer relationships. Customer relationships were calculated using the income approach. The following table sets forth the components of identified intangible assets associated with the P3 Acquisition and their estimated useful lives.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Fair Value</td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center">Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="width: 68%; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">Customer relationships</td> <td style="width: 1%; padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif">$</td> <td style="width: 14%; border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">151,273</td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="width: 14%; text-align: right; font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">7years</td></tr> <tr style="vertical-align: bottom; background-color: white; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">151,273</td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="text-align: right; font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table>    The Company determined the useful lives of intangible assets based on the expected future cash flows and contractual life associated with the respective assets. Customer relationships represent the expected future benefit from contracts and relationships which, at the date of acquisition, were reasonably anticipated to continue given the history and operating practices of P3.   Goodwill   Of the total estimated purchase price for the P3 Acquisition, $561,430 was allocated to goodwill. Goodwill represents the excess of the purchase price of the acquired business over the fair value of the underlying net tangible and intangible assets acquired. The goodwill recorded resulting from the acquisition is expected to be deductible for income tax purposes.

Note 7 Related Party Transactions   The Companys Chairman of the Board and CFO, Stephen Keaveney has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $10,000 and $26,000, respectively during the three and six months ending June 30, 2016. The Companys newly appointed CEO,James Driscoll has anemployment agreement effective June 7, 2016 that will pay him a monthly salary in the amount of $12,500 per month for remainder of 2016, $17,500 per month for the calendar year of 2017, $22,500 per month for the calendar year of 2018 and $25,000 per month for the calendar year of 2019. No payments have been made to James Driscoll during the three and six months ending June 30, 2016.   On January 25, 2016 board member William L. Ross and Jeffrey Cosman were each awarded 100,000 of shares of the Company in exchange for their services as board members. On April 25, 2016 board member James Driscoll was awarded 100,000 of shares of the Company in exchange for his services on the board and 1,000,000 non-qualified stock options for his position as CEO. On May 25, 2016, board member Phillip Crone was awarded 100,000 of shares the Company in exchange for his services on the board.   In addition, a shareholder of the Company has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $1,395 and $18,645 during the three and six months ended June 30, 2016, respectively. As of December 31, 2015, $17,000 was classified as a prepaid asset in the consolidated balance sheets related to the prepayment of consulting fees. No amounts were prepaid as of June 30, 2016.   Any amount owed for services performed through June 30, 2016 and remain unpaid are recorded as accrued labilities on the consolidated balance sheets.

Note 13 Subsequent Events   On July 6, 2016, the Company appointed Gary Meyer to the newly created position of Director of Compliance, providing oversight to its compounding pharmacy operations in the area of licensing, operational compliance and to interface with the appropriate regulatory bodies at the state and federal level. He worked as a Pharmacist in Charge for CRC Pharmacy from Aug 2015 to July 2016, Physicians Rx Pharmacy from April 2015 to July 2015, Dunwoody Pharmacy from 1995 to Feb 2015, Concord Pharmacy from 1992 to 1995 and Kroger Pharmacy in 1992.    Mr. Meyer has a bachelors of Science in Pharmacy from The University of Georgia.  Mr. Meyer holds a Georgia Board of Pharmacy license 1989- current, is a Past Board Member of the Pharmacy Franchise & Owners Association, a member of National Community Pharmacists Association, a member of Georgia Pharmacy Association, Member of the International Academy of Compounding Pharmacists, Member since 1995 of the Professional Compounding Centers of America, . He will report to the Companys CEO, James Driscoll. As part of his employment agreement he will receive 50,000 shares.   On August 2, 2016, the Board of Directors approved the consulting agreement with Acorn Management for market awareness, which calls for monthly payments starting at $7,500 per month and restricted common shares to be valued at $50,000 per month to be converted at fair value at month-end.

13308333

Inventories -Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. In addition, the Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.

Property and Equipment, net - Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed generally on a straight-line basis over the estimated useful lives of the assets. The cost of leasehold improvements are amortized either over the life of the improvement or the lease term, whichever is shorter. Significant improvements are capitalized and disposed or replaced property is written off. Maintenance and repairs are charged to expense in the period they are incurred. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts, and any gain or loss is included in earnings.

-190000

190000 190000

EX-101.SCH 7 tntyob-20160630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Unaudited Consolidated Statements of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Unaudited Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 1 - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 3 - Recent Developments link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 4 - Financial Condition and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 5 - Spin-Out and Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 6 - Acquisition link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 7 - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 8 - Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 9 - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 10 - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 11 - Warrants to Purchase Common Stock link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 12 - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note 13 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Note 5 - Spin-Out and Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Note 6 - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note 11 - Warrants to Purchase Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Note 3 - Recent Developments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Note 4 - Financial Condition and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Note 5 - Spin-Out and Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Note 6. Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Note 6. Acquisition (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Note 7 - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Note 8 - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Note 9 - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Note 10 - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Note 10 - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Note 11 - Warrants to Purchase Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Note 11 - Warrants to Purchase Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Note 12 - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Note 13 - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 tntyob-20160630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 tntyob-20160630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 tntyob-20160630_lab.xml XBRL LABEL FILE Common Stock Equity Components [Axis] Additional Paid-in Capital Accumulated Deficit Warrant [Member] Award Type [Axis] 2009 Employee, Director and Consultant Stock Option Plan (the " 2009 Plan") Plan Name [Axis] 2012 Employee, Director and Consultant Stock Option Plan (the "2012 Plan") Stephen Keaveney [Member] Title of Individual [Axis] Shareholder [Member] Chief Executive Officer [Member] Convertible Promissory Note [Member] Long-term Debt, Type [Axis] November 2014 Convertible Debentures (Series D) [Member] August 2014 Convertible Debentures (Series C) [Member] Convertible Promissory B Note [Member] Restricted Stock [Member] Board member [Member] Related Party [Axis] Minimum [Member] Range [Axis] Maximum [Member] Options Held [Member] Potential shares [Member] William L. Ross and Jeffrey Cosman [Member] Additional Paid-In Capital Subsequent Event [Member] Subsequent Event Type [Axis] Consulting agreement [Member] Future Awards [Member] Customer Relationships [Member] Finite-Lived Intangible Assets by Major Class [Axis] James Driscoll [Member] VP of Corporate Development [Member] P3 Convertible Notet [Member] Convertible Promissory B Note [Member] P3 Compounding of Georgia [Member] Jim Driscoll [Member] Acquisition [Member] Business Acquisition [Axis] Phillip Crone [Member] Director [Member] Convertible Promissory A Note [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer Is Entity a Voluntary Filer Is Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and Cash Equivalents Accounts receivable Inventory Prepaid expenses and other current assets Prepaid expenses - related party Total current assets Property and equipment, net Customer relationships Goodwill TOTAL ASSETS LIABILITIES Current liabilities Accounts payable Short-term loan Accrued interest Accrued liabilities Debentures payable Convertible note payable, net of discount Total current liabilities TOTAL LIABILITIES Commitments and Contingencies (Note 12) STOCKHOLDERS' DEFICIT Preferred stock, $0.01 par value - 10,000,000 shares authorized, none issued and outstanding as of June 30, 2016 and December 31, 2015 Common stock, $0.01 par value - 500,000,000 shares authorized, 13,175,000 shares issued and outstanding at June 30, 2016; $0.01 par value - 500,000,000 shares authorized, 11,765,000 shares issued and outstanding at December 31, 2015 Additional paid-in capital Accumulated deficit Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred stock par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] Net Sales Cost of sales Gross Profit Operating expenses: Research and development Selling, general and administrative Total operating expenses Operating Loss from Continuing Operations Interest expense, net Loss on debt extinguishment Loss From Continuing Operations before Income Taxes Provision for income taxes Net Loss From Continuing Operations Discontinued Operations (Note 5): Net Loss from discontinued operations, net of tax Other comprehensive gain, net of tax Comprehensive Loss from Discontinued Operations Net Loss Comprehensive Net Loss Net Loss from Continuing Operations Per Share - Basic and Diluted Net Loss from Discontinued Operations Per Share - Basic and Diluted Net Loss Per Share - Basic and Diluted Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted Statement [Table] Statement [Line Items] Beginning Balance, Amount Beginning Balance, Shares Sale of common stock, net of issuance cost, Amount Sale of common stock, net of issuance cost, Shares Shares issued to board members, Amount Shares issued to board members, Shares Shares issued to consulting members, Amount Shares issued to consulting members, Shares Shares issued for P3 Compounding of Georgia acquisition, Amount Shares issued for P3 Compounding of Georgia acquisition, Shares Shares issued to employee, Amount Shares issued to employee, Shares Common stock issued for convertible note payable, Amount Common stock issued for convertible note payable, Shares Discount related to issuance of note payable and allocated fair value to beneficial conversion feature Loss on debt extinguishment Stock compensation expense Net loss Ending Balance, Amount Ending Balance, Shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net Loss Adjustments to reconcile net loss to net cash used in operating activities: Loss from discontinued operations Accretion for debt discounts, warrants and issuance costs Stock-based option compensation Shares issued for board of director compensation Shares issued for consulting services Shares issued to employee Loss on debt extinguishment Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued interest and other liabilities Net Cash Used in Operating Activities Cash Flows from Investing Activities: Cash received from acquisition of P3 Compounding of Georgia Net Cash Provided by Investing Activities Cash Flows from Financing Activities: Proceeds from issuance of convertible note payable Sale of common stock, net of issuance costs Proceeds from short-term loan Net Cash Provided by Financing Activities Discontinued Operations: Operating activities Investing activities Financing activities Net Increase in Cash and Cash Equivalents for Discontinued Operations Net Decrease in Cash and Cash Equivalents for Continuing Operations Cash, Beginning of Period Cash, End of Period Non-cash Investing and Financing Transactions: Conversion of debt to common stock shares Discount cost related to issuance of convertible notes payable Acquisition of P3 Compounding of Georgia, net of cash acquired: Fair value of assets acquired Fair value of liabilities assumed Issuance of common stock for acquisition of P3 Debt obligation recorded as a result of acquisition Goodwill Organization, Consolidation and Presentation of Financial Statements [Abstract] Note 1 - Description of Business Accounting Policies [Abstract] Note 2 - Summary of Significant Accounting Policies Note 3 - Recent Developments Note 3 - Recent Developments Note 3 - Financial Condition and Going Concern Note 4 - Financial Condition and Going Concern Discontinued Operations and Disposal Groups [Abstract] Note 5 - Spin-Out and Discontinued Operations EX-101.PRE 11 tntyob-20160630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 08, 2016
Document And Entity Information
Entity Registrant Name	True Nature Holding, Inc.
Entity Central Index Key	0000802257
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,308,333
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2016

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (unaudited) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and Cash Equivalents	$ 20,571	$ 28,185
Accounts receivable	26,000
Inventory	111,668
Prepaid expenses and other current assets	30,179
Prepaid expenses - related party		17,000
Total current assets	188,418	45,185
Property and equipment, net	5,294
Customer relationships	151,273
Goodwill	561,430
TOTAL ASSETS	906,415	45,185
Current liabilities
Accounts payable	600,647	414,463
Short-term loan	44,350
Accrued interest	24,600	14,918
Accrued liabilities	46,569	13,325
Debentures payable	122,167	122,167
Convertible note payable, net of discount	224,962
Total current liabilities	1,063,295	564,873
TOTAL LIABILITIES	1,063,295	564,873
Commitments and Contingencies (Note 12)
STOCKHOLDERS' DEFICIT
Preferred stock, $0.01 par value - 10,000,000 shares authorized, none issued and outstanding as of June 30, 2016 and December 31, 2015
Common stock, $0.01 par value - 500,000,000 shares authorized, 13,175,000 shares issued and outstanding at June 30, 2016; $0.01 par value - 500,000,000 shares authorized, 11,765,000 shares issued and outstanding at December 31, 2015	131,750	117,650
Additional paid-in capital	3,119,918	3,917
Accumulated deficit	(3,408,548)	(641,255)
Total Stockholders' Deficit	(156,880)	(519,688)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 906,415	$ 45,185

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock par value	$ 0.01	$ 0.01
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value	$ 0.01	$ 0.01
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	11,765,000	11,765,000
Common stock shares outstanding	11,765,000	11,765,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net Sales
Cost of sales
Gross Profit
Operating expenses:
Research and development
Selling, general and administrative	1,679,986		2,512,355
Total operating expenses	1,679,986		2,512,355
Operating Loss from Continuing Operations	(1,679,986)		(2,512,355)
Interest expense, net	(58,720)		(64,938)
Loss on debt extinguishment	(190,000)		(190,000)
Loss From Continuing Operations before Income Taxes	(1,928,706)		(2,767,293)
Provision for income taxes
Net Loss From Continuing Operations	(1,928,706)		(2,767,293)
Discontinued Operations (Note 5):
Net Loss from discontinued operations, net of tax		(699,729)		(1,322,199)
Other comprehensive gain, net of tax		14,082		12,807
Comprehensive Loss from Discontinued Operations		(685,647)		(1,309,392)
Net Loss	(1,928,706)	(699,729)	(2,767,293)	(1,322,199)
Comprehensive Net Loss	$ (1,928,706)	$ (685,647)	$ (2,767,293)	$ (1,309,392)
Net Loss from Continuing Operations Per Share - Basic and Diluted	$ (0.15)		$ (0.22)
Net Loss from Discontinued Operations Per Share - Basic and Diluted		(1.28)		(2.43)
Net Loss Per Share - Basic and Diluted	$ (0.15)	$ (1.28)	$ (0.22)	$ (2.43)
Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted	12,687,478	545,386	12,368,961	543,996

XML 16 R5.htm IDEA: XBRL DOCUMENT

Unaudited Consolidated Statements of Changes in Stockholders' Deficit - 6 months ended Jun. 30, 2016 - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2015	$ 117,650	$ 3,917	$ (641,255)	$ (519,688)
Beginning Balance, Shares at Dec. 31, 2015	11,765,000			11,765,000
Sale of common stock, net of issuance cost, Amount	$ 1,200	49,800		$ 51,000
Sale of common stock, net of issuance cost, Shares	120,000
Shares issued to board members, Amount	$ 4,000	723,000		727,000
Shares issued to board members, Shares	400,000
Shares issued to consulting members, Amount	$ 4,100	402,400		406,500
Shares issued to consulting members, Shares	410,000
Shares issued for P3 Compounding of Georgia acquisition, Amount	$ 3,400	258,400		261,800
Shares issued for P3 Compounding of Georgia acquisition, Shares	340,000
Shares issued to employee, Amount	$ 1,250	433,750		435,000
Shares issued to employee, Shares	125,000
Common stock issued for convertible note payable, Amount	$ 150	16,213		$ 16,363
Common stock issued for convertible note payable, Shares	15,000			15,000
Discount related to issuance of note payable and allocated fair value to beneficial conversion feature		533,804		$ 533,804
Loss on debt extinguishment		190,000		190,000
Stock compensation expense		508,634		508,634
Net loss			(2,767,293)	(2,767,293)
Ending Balance, Amount at Jun. 30, 2016	$ 131,750	$ 3,119,918	$ (3,408,548)	$ (156,880)
Ending Balance, Shares at Jun. 30, 2016	13,175,000			11,765,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Unaudited Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities:
Net Loss	$ (2,767,293)	$ (1,322,199)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations		1,322,199
Accretion for debt discounts, warrants and issuance costs	40,129
Stock-based option compensation	508,634
Shares issued for board of director compensation	727,000
Shares issued for consulting services	406,500
Shares issued to employee	435,000
Loss on debt extinguishment	190,000
Changes in operating assets and liabilities:
Prepaid expenses and other assets	7,527
Accounts payable	150,762
Accrued interest and other liabilities	42,926
Net Cash Used in Operating Activities	(258,815)
Cash Flows from Investing Activities:
Cash received from acquisition of P3 Compounding of Georgia	10,201
Net Cash Provided by Investing Activities	10,201
Cash Flows from Financing Activities:
Proceeds from issuance of convertible note payable	160,000
Sale of common stock, net of issuance costs	51,000
Proceeds from short-term loan	30,000
Net Cash Provided by Financing Activities	241,000
Discontinued Operations:
Operating activities		(239,974)
Investing activities		(72,983)
Financing activities		314,838
Net Increase in Cash and Cash Equivalents for Discontinued Operations		1,881
Net Decrease in Cash and Cash Equivalents for Continuing Operations	(7,614)
Cash, Beginning of Period	28,185	14,119
Cash, End of Period	20,571	16,000
Non-cash Investing and Financing Transactions:
Conversion of debt to common stock shares		45,953
Discount cost related to issuance of convertible notes payable	575,167	274,122
Acquisition of P3 Compounding of Georgia, net of cash acquired:
Fair value of assets acquired	314,941
Fair value of liabilities assumed	35,422
Issuance of common stock for acquisition of P3	261,800
Debt obligation recorded as a result of acquisition	589,350
Goodwill	$ 561,430

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Note 1 - Description of Business

Note 1 – Description of Business

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Note 2 - Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Accounts Receivable -The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Accounts receivable are stated at the invoiced amount and are unsecured and require no collateral. Charges to bad debt are based on both historical write-offs and specifically identified receivables.

Inventories -Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. In addition, the Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.

Business Combinations -The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts; anddiscount rates utilized in valuation estimates.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Recent Developments

6 Months Ended

Jun. 30, 2016

Note 3 - Recent Developments

Note 3 - Recent Developments

Note 3 – Recent Developments

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Financial Condition and Going Concern

6 Months Ended

Jun. 30, 2016

Note 3 - Financial Condition and Going Concern

Note 4 - Financial Condition and Going Concern

Note 4 – Financial Condition and Going Concern

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Spin-Out and Discontinued Operations

6 Months Ended

Jun. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Note 5 - Spin-Out and Discontinued Operations

Note 5 – Spin-Out and Discontinued Operations

The results of operations associated with discontinued operations were as follows:

		Three Months Ended			Six Months Ended
		June 30, 2015			June 30, 2015
Net Sales	$	66,458		$	185,137
Cost of sales		27,894			90,023
Gross Profit		38,564			95,114

Operating Expenses:
Research and development		186,950			381,649
Selling, general and administrative		232,596			484,862
Total operating expenses		419,546			866,511

Operating Loss from Discontinued Operations		(380,982	)		(771,397	)

Other Expense:
Interest expense, net		(318,747	)		(550,802	)

Net Loss from Discontinued Operations	$	(699,729	)		(1,322,199	)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		14,082			12,807
Comprehensive Loss from Discontinued Operations	$	(685,647	)	$	(1,309,392	)

Our educational business was fully disposed of in December 2015. As a result, there were no assets or liabilities of discontinued operations as of December 31, 2015 or in subsequent periods.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Acquisition

6 Months Ended

Jun. 30, 2016

Note 6 - Acquisition

Note 6 - Acquisition

Note 6 - Acquisition

On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC,(“P3”).P3 received Georgia Board of Pharmacy approval for the transaction at the end of June 2016 and the transaction closed effective June 30, 2016. P3 is a full service compounding pharmacy with both sterile and non-sterile expertise headquarter in Atlanta, Georgia. The medicines that P3 compounds include bio-identical hormone replacement therapy, transdermal pain creams, wellness compounding, individualized and prescriptions.The transaction included the acquisition of identifiable assets, customer listings and intellectual properties included in the P3’s library of specialized formulations.

The fair value of the consideration paid pertaining to the acquisition of P3 was $851,150. Consideration for the transaction was structured as follows:

•

An interest-free note for $150,000 with no interest to be paid in full via wire transfer on the maturity date of August 16, 2016;

▪

$425,000 convertible note with a term of 12 months and a 6% interest rate, with the first installment due June 1, 2016, and convertible into common stock of True Nature at a rate of $1.25 per share (which is 340,000 shares of common stock), less a short-term financing for $14,350 that the Company provided to Integrity for working capital purposes;

▪

A $425,000 convertible note with no interest, which automatically converted 340,000 shares of common stock with a fair value of $261,800 based on the closing price of the True Nature’s common stock on June 30, 2016.

Allocation of Consideration Transferred

Cash and cash equivalents	$	10,201
Accounts receivable		26,000
Inventories		111,668
Other current assets		20,706
Furniture and equipment		5,294
Customer list		151,273
Total identifiable assets acquired		325,142
Accounts payable and accrued expenses		35,422
Total liabilities assumed		35,422
Total identifiable assets less liabilities assumed		289,720
Goodwill		561,430
Net assets acquired	$	851,150

The fair value of the transaction and related purchase price allocation was based on a third-party valuation obtained by the Company.

Intangible Assets-Customer Relationships

	Fair Value		Useful Life
Customer relationships	$	151,273	7years
	$	151,273

Goodwill

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Related Party Transactions

6 Months Ended

Jun. 30, 2016

Note 7 - Related Party Transactions

Note 7 – Related Party Transactions

The Company’s Chairman of the Board and CFO, Stephen Keaveney has a consulting agreement in the amount of $10,000 per month for professional fees and was paid $10,000 and $26,000, respectively during the three and six months ending June 30, 2016. The Company’s newly appointed CEO,James Driscoll has anemployment agreement effective June 7, 2016 that will pay him a monthly salary in the amount of $12,500 per month for remainder of 2016, $17,500 per month for the calendar year of 2017, $22,500 per month for the calendar year of 2018 and $25,000 per month for the calendar year of 2019. No payments have been made to James Driscoll during the three and six months ending June 30, 2016.

Any amount owed for services performed through June 30, 2016 and remain unpaid are recorded as accrued labilities on the consolidated balance sheets.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Debt

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Note 8 - Debt

Note 8 – Debt

Convertible Promissory Notes

Pursuant to the terms of the Convertible Note A, the Company is obligated to pay monthly installments of not less than $1,000 the first of each month commencing the month following the execution of this note until its full maturity on September 16, 2016 at which time the Company is obligated to repay the full principal amount of the Convertible Note A. The Convertible Note A is convertible by the holder at any time into shares of the Company’s common stock at an effective conversion price of $1.00 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note A to the shares and the note based on relative fair values, and the amount allocated to the shares of $16,364 was recorded as a discount against the note, with an offsetting entry to additional paid-in capital. The beneficial conversion feature of $16,364 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of June 30, 2016, the carrying value of this Convertible Note A was $45,872 and accrued interest expense of $1,080. For the three and six months ended June 30, 2016, debt discount amortization related to the Convertible Note A was $16,274 and $18,599, respectively and its related interest expense was$1,820 and $2,080, respectively.

On May 19, 2016, the Company issued a 10% Convertible Promissory Note (the “Convertible Note B”) in the principal amount of $100,000 to the Lender. Pursuant to the terms of the Convertible Note B, on the date thereof, the Company issued the Convertible Note B to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note B. Upon issuance the lender was awarded 66,666 warrants to purchase common stock of the Companyat an exercise price of $2.50 for a term of twenty-four months.

Pursuant to the terms of the Convertible Note B, the Company is obligated to repay the full principal amount of the Convertible Note B with any unpaid interest upon the date of maturity, June 19, 2017. The Convertible Note Bis convertible by the holder at any time into shares of the Company’s common stock at an effective conversion price of $1.50 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note B to the shares and the note based on relative fair values, and the amount allocated to the shares of $39,887 was recorded as a discount against the note, with an offsetting entry to additional paid-in capital. The beneficial conversion feature of $52,553 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. As of June 30, 2016, the carrying value of this Convertible Note B was $29,090and accrued interest expense of $1,167.For the three and six months ended June 30, 2016, debt discount amortization related to the Convertible Note Bwas $21,530 and its related interest expense was $1,167.

Short-term Loan

As a result of the acquisition of P3 Compounding of Georgia, LLC the Company had a short-term loanwith a loan agency for a principal amount of $52,000 for the purchase of future sales and credit card receivables of P3. Under the terms of the receivable purchase agreement, the Company purchased an advance of $50,000 plus $2,000 for origination costs with a 10.5% daily interest rate to be repaid over 160 days at a repayment amount of $451.75 per day. Upon maturity of the loan the total repayment amount will be $72,280.As of June 30, 2016, the carrying value of this short term loan was $44,350. For the three and six months ended June 30, 2016, no interest expense related to this loan was recorded in the Company’s consolidated financial statements as the effective date of acquisition was the last day of the quarter.

August 2014 Convertible Debentures (Series C)

November 2014 Convertible Debentures (Series D)

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Stockholders' Deficit

6 Months Ended

Jun. 30, 2016

Stockholders' Equity Note [Abstract]

Note 9 - Stockholders' Deficit

Note 9 – Stockholders’ Deficit

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Stock-Based Compensation

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Note 10 - Stock-Based Compensation

Note 10 – Stock-Based Compensation

In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of spin-out Companyin fiscal 2014. These options issued are outside of the 2009 and 2012 Plans.

On June 1, 2016Jim Driscoll was granted for his position as Chief Executive Officer(CEO) of the Company options to purchase up to 1,000,000 shares of Common Stock outside ofthe Company’s 2009 and 2012 stock option plans (the “Option Agreement”). These options covered 250,000 shares at an exerciseprice of $1.00 per share to be granted immediately and three additional tranches of 250,000 shares each at an exercise price of $1.50, $2.00 and $2.50 per share,respectively. The remaining three tranches will vest equally over the next three years with the first fully vesting on May 31, 2017 through May 31, 2019. The term of the options will be for a period of five years and may be exercised at any time as to the vested shares.

During the three and six months ended June 30, 2016, the Company recorded stock compensation expense related to the options granted to Mr. Driscoll of $496,668 and has unrecognized stock expense of $1,040,793 to be recorded over the vesting period. The grant-date fair value of options was estimated using the Black-Scholes option pricing model. The per share weighted average fairvalue of stock options granted for Mr. Driscoll wasa range of $1.35-$1.76and was determined using the following assumptions: expected pricevolatility is 80.39%, risk-free interest rate of 1.39%, zero expected dividend yield, and 4.0 years expected life of options. Theexpected term of options granted is based on the simplified method in accordance with Securities and Exchange CommissionStaff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. TheCompany makes assumptions with respect to expected stock price volatility based on the average historical volatility of peerswith similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturitiessimilar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day.

A summary of options issued, exercised and cancelled are as follows:

	Shares		Weighted- Average Exercise Price ($)		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2015		67,879	$	21.40		7.17		—
Granted		1,000,000		1.75		5.00		—
Cancelled		—		—		—		—

Outstanding at June 30, 2016		1,067,879	$	3.00		5.22		—

Exercisable at June 30, 2016		354,911	$	4.99		4.95		—

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Warrants to Purchase Common Stock

6 Months Ended

Jun. 30, 2016

Note 9 - Warrants to Purchase Common Stock

Note 11 - Warrants to Purchase Common Stock

Note 11 – Warrants to Purchase Common Stock

Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized.All warrants outstanding as of June 30, 2016 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows:

	Shares			Weighted- Average Exercise Price ($)		Weighted-Average Remaining Contractual Term
Outstanding at December 31, 2015		78,462		$	29.55		3.43
Granted		66,666			2.50		2.00
Expired		(2,475	)		50.50		—

Outstanding at June 30, 2016		142,653		$	17.42		2.50

Exercisable at June 30, 2016		142,653		$	17.42		2.50

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Commitments and Contingencies

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Note 12 - Commitments and Contingencies

Note 12 – Commitments and Contingencies

Legal

National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No.. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 13 - Subsequent Events

6 Months Ended

Jun. 30, 2016

Subsequent Events [Abstract]

Note 13 - Subsequent Events

Note 13 – Subsequent Events

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation - The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information, with the instructions to Form 10-Q and with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, these consolidated financial statements contain all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position at June 30, 2016, the results of operations for the three months and six months ended June 30, 2016 and 2015, and cash flows for the three months and six months ended June 30, 2016 and 2015. The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s audited consolidated financial statements and management’s discussion and analysis included in the Company’s annual report on Form 10-K for the year ended December 31, 2015. In addition, refer to Note 5 regarding the spin-out of the educational business and related discontinued operations classification pertaining to the fiscal 2015 period. Common stock share and per share amounts in these financial statements have been retroactively adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.
Use of Estimates	Use of Estimates - The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.
Per Share Data	Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments. The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of June 30, 2016, the Company had 142,652warrants, 1,067,879 options, 135,037 potential shares which may be issued resulting from the provisions of convertible notes, respectively. As of June 30, 2015, the Company had 77,640 warrants, 67,483 options, 316,721 potential shares which may be issued resulting from the provisions of convertible notes, respectively.
Accounts Receivable	Accounts Receivable -The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Accounts receivable are stated at the invoiced amount and are unsecured and require no collateral. Charges to bad debt are based on both historical write-offs and specifically identified receivables.
Inventories	Inventories -Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. In addition, the Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.
Property and Equipment, net	Property and Equipment, net - Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed generally on a straight-line basis over the estimated useful lives of the assets. The cost of leasehold improvements are amortized either over the life of the improvement or the lease term, whichever is shorter. Significant improvements are capitalized and disposed or replaced property is written off. Maintenance and repairs are charged to expense in the period they are incurred. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts, and any gain or loss is included in earnings.
Business Combinations	Business Combinations -The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts; anddiscount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.
Goodwill and Intangible Assets	Goodwill and Intangible Assets - Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill and intangibles under ASC Topic 350, Intangibles – Goodwill and Other, which does not permit amortization, but requires the Company to test goodwill and other indefinite-lived assets for impairment annually or whenever events or circumstances indicate impairment may exist.
Recently Issued Accounting Standards	Recently Issued Accounting Standards-In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective for annual periods beginning on or after December 15, 2016, including interim periods within those annual periods. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. In August 2014, the FASB issued new accounting guidance which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Company’s consolidated balance sheets and results of operations due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Company’s cash flows. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. This guidance will be effective in the first quarter of fiscal year 2017 and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 5 - Spin-Out and Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Results of operations associated with discontinued operations

The results of operations associated with discontinued operations were as follows:

		Three Months Ended			Six Months Ended
		June 30, 2015			June 30, 2015
Net Sales	$	66,458		$	185,137
Cost of sales		27,894			90,023
Gross Profit		38,564			95,114

Operating Expenses:
Research and development		186,950			381,649
Selling, general and administrative		232,596			484,862
Total operating expenses		419,546			866,511

Operating Loss from Discontinued Operations		(380,982	)		(771,397	)

Other Expense:
Interest expense, net		(318,747	)		(550,802	)

Net Loss from Discontinued Operations	$	(699,729	)		(1,322,199	)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		14,082			12,807
Comprehensive Loss from Discontinued Operations	$	(685,647	)	$	(1,309,392	)

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 6 - Acquisition (Tables)

6 Months Ended

Jun. 30, 2016

Note 6 - Acquisition Tables

Estimated fair values of the assets acquired and liabilities

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date based on a fair value acquisition price of $876,150 pertaining to the consideration provided.

Cash and cash equivalents	$	10,201
Accounts receivable		26,000
Inventories		111,668
Other current assets		20,706
Furniture and equipment		5,294
Customer list		151,273
Total identifiable assets acquired		325,142
Accounts payable and accrued expenses		35,422
Total liabilities assumed		35,422
Total identifiable assets less liabilities assumed		289,720
Goodwill		561,430
Net assets acquired	$	851,150

Components of identified intangible assets associated with acquisition and their estimated useful lives.

The following table sets forth the components of identified intangible assets associated with the P3 Acquisition and their estimated useful lives.

	Fair Value		Useful Life
Customer relationships	$	151,273	7 years
	$	151,273

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 10 - Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of options issued, exercised and cancelled

A summary of options issued, exercised and cancelled are as follows:

	Shares		Weighted- Average Exercise Price ($)		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2015		67,879	$	21.40		7.17		—
Granted		1,000,000		1.75		5.00		—
Cancelled		—		—		—		—

Outstanding at June 30, 2016		1,067,879	$	3.00		5.22		—

Exercisable at June 30, 2016		354,911	$	4.99		4.95		—

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 11 - Warrants to Purchase Common Stock (Tables)

6 Months Ended

Jun. 30, 2016

Note 9 - Warrants to Purchase Common Stock

Summary of warrants issued, exercised and expired

A summary of warrants issued, exercised and expired are as follows:

	Shares			Weighted- Average Exercise Price ($)		Weighted-Average Remaining Contractual Term
Outstanding at December 31, 2015		78,462		$	29.55		3.43
Granted		66,666			2.50		2.00
Expired		(2,475	)		50.50		—

Outstanding at June 30, 2016		142,653		$	17.42		2.50

Exercisable at June 30, 2016		142,653		$	17.42		2.50

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Narrative) - shares	1 Months Ended	6 Months Ended
	Jan. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Reverse spilit	1 for 101
Potential shares [Member]
Antidilutive securities excluded from computation of earnings per share, amount		135,037	316,721
Options Held [Member]
Antidilutive securities excluded from computation of earnings per share, amount		1,067,879	67,483
Warrant [Member]
Reverse spilit		1 for 101
Antidilutive securities excluded from computation of earnings per share, amount		142,652	77,640

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 3 - Recent Developments (Details Narrative) - USD ($)	May 20, 2016	Apr. 04, 2016
Note 3 - Recent Developments Details Narrative
Purchase consideration		$ 450,000
Expenses related to acquisition	$ 30,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 4 - Financial Condition and Going Concern (Details Narrative) - USD ($)	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Note 3 - Financial Condition and Going Concern
Cash and Cash Equivalents	$ 20,571	$ 28,185	$ 16,000	$ 14,119
Current liabilities	$ 1,063,295	$ 564,873

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 5 - Spin-Out and Discontinued Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Net Sales		$ 66,458		$ 185,137
Cost of sales		27,894		90,023
Gross Profit		38,564		95,114
Operating expenses:
Research and development		186,950		381,649
Selling, general and administrative		232,596		484,862
Total operating expenses		419,546		866,511
Operating Loss from Discontinued Operations		(380,982)		(771,397)
Other Expense:
Interest expense, net		(318,747)		(550,802)
Net Loss from Discontinued Operations		(699,729)		(1,322,199)
Other Comprehensive Loss Net of Tax:
Foreign currency translation adjustments		14,082		12,807
Comprehensive Loss from Discontinued Operations		$ (685,647)		$ (1,309,392)

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 6. Acquisition (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Note 6. Acquisition Details
Cash and cash equivalents	$ 10,201
Accounts receivable	26,000
Inventories	111,668
Other current assets	20,706
Furniture and equipment	5,294
Customer list	151,273
Total identifiable assets acquired	325,142
Accounts payable and accrued expenses	35,422
Total liabilities assumed	35,422
Total identifiable assets less liabilities assumed	289,720
Goodwill	561,430
Net assets acquired	$ 851,150

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 6. Acquisition (Details 1)	6 Months Ended
Note 6. Acquisition (Details 1)	Jun. 30, 2016 USD ($)
Fair Value	$ 151,273
Customer Relationships [Member]
Fair Value	$ 151,273
Useful Life	7 years

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 7 - Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended
	May 25, 2016	Jan. 25, 2016	Jun. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Prepaid expenses - related party					$ 4,250	$ 17,000
Shareholder [Member]
Monthly professional fees				10,000
Professional fees paid			1,395	18,645
Stephen Keaveney [Member]
Monthly professional fees				10,000
Professional fees paid			$ 26,000	10,000
William L. Ross and Jeffrey Cosman [Member]
Shares purchased		100,000
James Driscoll [Member]
Professional fees paid				$ 12,500
Phillip Crone [Member]
Shares purchased	100,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 8 - Debt (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended
Note 8 - Debt (Details Narrative) - USD ($)	May 19, 2016	Mar. 18, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Convertible Promissory A Note [Member]
Convertible Debentures, Carrying Value			$ 45,872		$ 45,872
Accrued Interest			1,080		1,080
Convertible Promissory B Note [Member]
Convertible Debentures, Carrying Value			29,090		29,090
Accrued Interest			1,167		1,167
Debt discount amortization related to the Convertible Note					1,167
Convertible Promissory Note [Member]
Convertible promissory note principal amount		$ 60,000
Convertible Debentures, Face Value		$ 16,364
Debt instrument conversion price		$ 1.00
Convertible Debentures, Carrying Value				$ 29,598
Accrued Interest				260
Interest expense related to the Debenture			1,820		2,080
Debt discount amortization related to the Convertible Note			16,274		18,599
Convertible Promissory B Note [Member]
Restricted common shares awarded	39,887	15,000
Interest rate		12.00%
Maturity date	Jun. 19, 2017	Sep. 16, 2016
Debt instrument conversion price	$ 1.50
Debt discount amortization related to the Convertible Note	$ 52,553	$ 16,364	21,530
Obligated to pay monthly installments		$ 1,000
November 2014 Convertible Debentures (Series D) [Member]
Convertible Debentures, Face Value						$ 10,000
Interest rate						12.00%
Maturity date						Oct. 31, 2015
Debt instrument conversion price						$ 16.67
Warrants to purchase of common stock						495
Warrants to purchase of common stock exercise price						$ 20.20
Warrants to purchase of common stock term						5 years
Convertible Debentures, Carrying Value			11,334		11,334	$ 11,334
Accrued Interest			2,267		2,267
Interest expense related to the Debenture			340		686
August 2014 Convertible Debentures (Series C) [Member]
Convertible Debentures, Face Value						$ 100,000
Interest rate						10.00%
Maturity date						Oct. 31, 2015
Debt instrument conversion price						$ 20.20
Warrants to purchase of common stock						4,950
Warrants to purchase of common stock exercise price						$ 20.20
Warrants to purchase of common stock term						5 years
Convertible Debentures, Carrying Value			110,833		110,833	$ 110,833
Accrued Interest			19,950		19,950
Interest expense related to the Debenture				$ 3,325	6,613
P3 Compounding of Georgia [Member]
Convertible promissory note principal amount			52,000		$ 52,000
Interest rate					10.50%
Convertible Debentures, Carrying Value			44,350		$ 44,350
Advance			$ 50,000		$ 50,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 9 - Stockholders' Deficit (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Gross proceeds from sale of common stock	$ 60,000
Gross proceeds from sale of common stock shares	120,000
Common stock shares issued price per share	$ 0.50		$ 0.50
Securities issuance costs commissions paid to broker-dealers	$ 6,000
Common stock shares issued for services rendered	9,000
Conversion of six-month convertible promissory note to common stock	15,000
Conversion of six-month convertible promissory note common stock, value	$ 16,363
Gross proceeds from convertible note payable	160,000
Debt beneficial conversion feature for convertible note payable	$ 108,804
Restricted Stock [Member]
Common stock shares issued for services rendered	410,000
Restricted Stock [Member] \| P3 Convertible Notet [Member]
Common stock shares issued price per share	$ 1.25
Conversion of six-month convertible promissory note to common stock	340,000
Conversion of six-month convertible promissory note common stock, value	$ 425,000
Restricted Stock [Member] \| VP of Corporate Development [Member]
Common stock shares issued price per share	$ 3.48
Common stock shares issued for services rendered	125,000
Restricted Stock [Member] \| Board member [Member]
Common stock shares issued price per share			1.45
Common stock shares issued for services rendered	400,000
Restricted Stock [Member] \| Minimum [Member]
Common stock shares issued price per share			0.90
Restricted Stock [Member] \| Maximum [Member]
Common stock shares issued price per share			$ 1.45

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 10 - Stock-Based Compensation (Details)	6 Months Ended
Note 10 - Stock-Based Compensation (Details)	Jun. 30, 2016 USD ($) $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding \| shares	67,879
Option Granted \| shares	1,000,000
Option Cancelled \| shares
Options Outstanding \| shares	1,067,879
Options exercisable at End \| shares	354,911
Outstanding at Beginning, Weighted-Average Exercise Price \| $ / shares	$ 21.40
Weighted- Average Exercise Price, Granted \| $ / shares	1.75
Weighted- Average Exercise Price, Cancelled \| $ / shares
Outstanding at Ending, Weighted-Average Exercise Price \| $ / shares	3.00
Weighted- Average exercisable at End \| $ / shares	$ 4.99
Weighted- Average Remaining Contractual Term, Beginning balance	7 years 2 months 1 day
Weighted- Average Remaining Contractual Term, Granted	5 years
Weighted- Average Remaining Contractual Term, Ending Balance	5 years 2 months 19 days
Weighted- Average Remaining Contractual Term, exercisable at End	4 years 11 months 12 days
Aggregate Intrinsic Value \| $
Aggregate Intrinsic Value, exercisable at End \| $

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 10 - Stock-Based Compensation (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 01, 2016	Jan. 31, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Mar. 31, 2016	Dec. 31, 2014
Reverse spilit		1 for 101
Options Outstanding			1,067,879	1,067,879		67,879	67,879
Unrecognized stock compensation expense			$ 1,041,377	$ 1,041,377			$ 780
Unrecognized stock compensation expense recognition period				1 year 11 months 1 day
Share based compensation				$ 508,634
Jim Driscoll [Member]
Number of option granted	250,000
Number of option granted, exercise price	$ 1.00
Unrecognized stock compensation expense	$ 1,040,793
Share based compensation			$ 496,668	$ 496,668
Options to purchase common stock	1,000,000
Expected price volatility	80.39%
Risk-free interest rate	1.39%
Expected dividend yield	0.00%
Expected life of options	4 years
Chief Executive Officer [Member]
Options Outstanding								24,753
2009 Employee, Director and Consultant Stock Option Plan (the " 2009 Plan")
Reverse spilit						1 for 101
Authorized option pool						18,152
Stock option description						Stock options typically vest over a three-year period and have a life of ten years from the date granted.
Shares available for awards			3,610	3,610
2012 Employee, Director and Consultant Stock Option Plan (the "2012 Plan")
Reverse spilit						1 for 101
Authorized option pool						74,257
Stock option description						Stock options typically vest over a three year period and have a life of ten years from the date granted.
Shares available for awards			45,673	45,673

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 11 - Warrants to Purchase Common Stock (Details)	6 Months Ended
Note 11 - Warrants to Purchase Common Stock (Details)	Jun. 30, 2016 $ / shares shares
Options Outstanding \| shares	67,879
Options Granted \| shares	1,000,000
Options Expired \| shares
Options Outstanding \| shares	1,067,879
Options exercisable at End \| shares	354,911
Outstanding at Beginning, Weighted-Average Exercise Price \| $ / shares	$ 21.40
Weighted- Average Exercise Price, Granted \| $ / shares	1.75
Weighted- Average Exercise Price, Expired \| $ / shares
Outstanding at Ending, Weighted-Average Exercise Price \| $ / shares	3.00
Weighted- Average exercisable at End \| $ / shares	$ 4.99
Weighted- Average Remaining Contractual Term, Beginning balance	7 years 2 months 1 day
Weighted- Average Remaining Contractual Term, Granted	5 years
Weighted- Average Remaining Contractual Term, Ending Balance	5 years 2 months 19 days
Weighted- Average Remaining Contractual Term, exercisable at End	4 years 11 months 12 days
Warrant [Member]
Options Outstanding \| shares	78,462
Options Granted \| shares	66,666
Options Expired \| shares	(2,475)
Options Outstanding \| shares	142,653
Options exercisable at End \| shares	142,653
Outstanding at Beginning, Weighted-Average Exercise Price \| $ / shares	$ 29.55
Weighted- Average Exercise Price, Granted \| $ / shares	2.50
Weighted- Average Exercise Price, Expired \| $ / shares	50.50
Outstanding at Ending, Weighted-Average Exercise Price \| $ / shares	17.42
Weighted- Average exercisable at End \| $ / shares	$ 17.42
Weighted- Average Remaining Contractual Term, Beginning balance	3 years 5 months 5 days
Weighted- Average Remaining Contractual Term, Granted	2 years
Weighted- Average Remaining Contractual Term, Ending Balance	2 years 6 months
Weighted- Average Remaining Contractual Term, exercisable at End	2 years 6 months

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 11 - Warrants to Purchase Common Stock (Details Narrative)	1 Months Ended	6 Months Ended
	Jan. 31, 2016	Jun. 30, 2016
Reverse spilit	1 for 101
Warrant [Member]
Reverse spilit		1 for 101
Warrants expires through		Dec. 31, 2019

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 12 - Commitments and Contingencies (Details Narrative)	1 Months Ended
	Dec. 16, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Damages sought	$ 177,270
Interest rate	12.00%

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 13 - Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Aug. 02, 2016	Jul. 06, 2016
Consulting agreement [Member]
Officers compensation	$ 7,500
Common stock issued as compensation	50,000
Director [Member]
Common stock issued as compensation		50,000

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 84 218 1 false 32 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://trunity.co/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (unaudited) Sheet http://trunity.co/role/BalanceSheets Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://trunity.co/role/BalanceSheetsParenthetical Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss Sheet http://trunity.co/role/UnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss Unaudited Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Unaudited Consolidated Statements of Changes in Stockholders' Deficit Sheet http://trunity.co/role/UnauditedConsolidatedStatementsOfChangesInStockholdersDeficit Unaudited Consolidated Statements of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Unaudited Consolidated Statements of Cash Flows Sheet http://trunity.co/role/UnauditedConsolidatedStatementsOfCashFlows Unaudited Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Note 1 - Description of Business Sheet http://trunity.co/role/Note1-DescriptionOfBusiness Note 1 - Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://trunity.co/role/Note2-SummaryOfSignificantAccountingPolicies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Note 3 - Recent Developments Sheet http://trunity.co/role/Note3-RecentDevelopments Note 3 - Recent Developments Notes 9 false false R10.htm 00000010 - Disclosure - Note 4 - Financial Condition and Going Concern Sheet http://trunity.co/role/Note4-FinancialConditionAndGoingConcern Note 4 - Financial Condition and Going Concern Notes 10 false false R11.htm 00000011 - Disclosure - Note 5 - Spin-Out and Discontinued Operations Sheet http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperations Note 5 - Spin-Out and Discontinued Operations Notes 11 false false R12.htm 00000012 - Disclosure - Note 6 - Acquisition Sheet http://trunity.co/role/Note6-Acquisition Note 6 - Acquisition Notes 12 false false R13.htm 00000013 - Disclosure - Note 7 - Related Party Transactions Sheet http://trunity.co/role/Note5-RelatedPartyTransactions Note 7 - Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Note 8 - Debt Sheet http://trunity.co/role/Note5-ConvertibleDebt Note 8 - Debt Notes 14 false false R15.htm 00000015 - Disclosure - Note 9 - Stockholders' Deficit Sheet http://trunity.co/role/Note7-StockholdersDeficit Note 9 - Stockholders' Deficit Notes 15 false false R16.htm 00000016 - Disclosure - Note 10 - Stock-Based Compensation Sheet http://trunity.co/role/Note8-Stock-basedCompensation Note 10 - Stock-Based Compensation Notes 16 false false R17.htm 00000017 - Disclosure - Note 11 - Warrants to Purchase Common Stock Sheet http://trunity.co/role/Note11-WarrantsToPurchaseCommonStock Note 11 - Warrants to Purchase Common Stock Notes 17 false false R18.htm 00000018 - Disclosure - Note 12 - Commitments and Contingencies Sheet http://trunity.co/role/Note10-CommitmentsAndContingencies Note 12 - Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Note 13 - Subsequent Events Sheet http://trunity.co/role/Note11-SubsequentEvents Note 13 - Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies) Sheet http://trunity.co/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies Note 2 - Summary of Significant Accounting Policies (Policies) Policies http://trunity.co/role/Note2-SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Note 5 - Spin-Out and Discontinued Operations (Tables) Sheet http://trunity.co/role/Note5-Spin-outAndDiscontinuedOperationsTables Note 5 - Spin-Out and Discontinued Operations (Tables) Tables http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperations 21 false false R22.htm 00000022 - Disclosure - Note 6 - Acquisition (Tables) Sheet http://trunity.co/role/Note6-AcquisitionTables Note 6 - Acquisition (Tables) Tables http://trunity.co/role/Note6-Acquisition 22 false false R23.htm 00000023 - Disclosure - Note 10 - Stock-Based Compensation (Tables) Sheet http://trunity.co/role/Note7-Share-basedCompensationTables Note 10 - Stock-Based Compensation (Tables) Tables http://trunity.co/role/Note8-Stock-basedCompensation 23 false false R24.htm 00000024 - Disclosure - Note 11 - Warrants to Purchase Common Stock (Tables) Sheet http://trunity.co/role/Note8-WarrantsToPurchaseCommonStockTables Note 11 - Warrants to Purchase Common Stock (Tables) Tables http://trunity.co/role/Note11-WarrantsToPurchaseCommonStock 24 false false R25.htm 00000025 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Narrative) Sheet http://trunity.co/role/Note2-SummaryOfSignificantAccountingPoliciesDetailsNarrative Note 2 - Summary of Significant Accounting Policies (Details Narrative) Details http://trunity.co/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies 25 false false R26.htm 00000026 - Disclosure - Note 3 - Recent Developments (Details Narrative) Sheet http://trunity.co/role/Note3-RecentDevelopmentsDetailsNarrative Note 3 - Recent Developments (Details Narrative) Details http://trunity.co/role/Note3-RecentDevelopments 26 false false R27.htm 00000027 - Disclosure - Note 4 - Financial Condition and Going Concern (Details Narrative) Sheet http://trunity.co/role/Note3-FinancialConditionAndGoingConcernDetailsNarrative Note 4 - Financial Condition and Going Concern (Details Narrative) Details http://trunity.co/role/Note4-FinancialConditionAndGoingConcern 27 false false R28.htm 00000028 - Disclosure - Note 5 - Spin-Out and Discontinued Operations (Details) Sheet http://trunity.co/role/Note4-Spin-outAndDiscontinuedOperationsDetails Note 5 - Spin-Out and Discontinued Operations (Details) Details http://trunity.co/role/Note5-Spin-outAndDiscontinuedOperationsTables 28 false false R29.htm 00000029 - Disclosure - Note 6. Acquisition (Details) Sheet http://trunity.co/role/Note6.AcquisitionDetails Note 6. Acquisition (Details) Details 29 false false R30.htm 00000030 - Disclosure - Note 6. Acquisition (Details 1) Sheet http://trunity.co/role/Note6.AcquisitionDetails1 Note 6. Acquisition (Details 1) Details 30 false false R31.htm 00000031 - Disclosure - Note 7 - Related Party Transactions (Details Narrative) Sheet http://trunity.co/role/Note5-RelatedPartyTransactionsDetailsNarrative Note 7 - Related Party Transactions (Details Narrative) Details http://trunity.co/role/Note5-RelatedPartyTransactions 31 false false R32.htm 00000032 - Disclosure - Note 8 - Debt (Details Narrative) Sheet http://trunity.co/role/Note6-DebtDetailsNarrative Note 8 - Debt (Details Narrative) Details http://trunity.co/role/Note5-ConvertibleDebt 32 false false R33.htm 00000033 - Disclosure - Note 9 - Stockholders' Deficit (Details Narrative) Sheet http://trunity.co/role/Note7-StockholdersDeficitDetailsNarrative Note 9 - Stockholders' Deficit (Details Narrative) Details http://trunity.co/role/Note7-StockholdersDeficit 33 false false R34.htm 00000034 - Disclosure - Note 10 - Stock-Based Compensation (Details) Sheet http://trunity.co/role/Note8-Stock-basedCompensationDetails Note 10 - Stock-Based Compensation (Details) Details http://trunity.co/role/Note7-Share-basedCompensationTables 34 false false R35.htm 00000035 - Disclosure - Note 10 - Stock-Based Compensation (Details Narrative) Sheet http://trunity.co/role/Note8-Stock-basedCompensationDetailsNarrative Note 10 - Stock-Based Compensation (Details Narrative) Details http://trunity.co/role/Note7-Share-basedCompensationTables 35 false false R36.htm 00000036 - Disclosure - Note 11 - Warrants to Purchase Common Stock (Details) Sheet http://trunity.co/role/Note9-WarrantsToPurchaseCommonStockDetails Note 11 - Warrants to Purchase Common Stock (Details) Details http://trunity.co/role/Note8-WarrantsToPurchaseCommonStockTables 36 false false R37.htm 00000037 - Disclosure - Note 11 - Warrants to Purchase Common Stock (Details Narrative) Sheet http://trunity.co/role/Note9-WarrantsToPurchaseCommonStockDetailsNarrative Note 11 - Warrants to Purchase Common Stock (Details Narrative) Details http://trunity.co/role/Note8-WarrantsToPurchaseCommonStockTables 37 false false R38.htm 00000038 - Disclosure - Note 12 - Commitments and Contingencies (Details Narrative) Sheet http://trunity.co/role/Note10-CommitmentsAndContingenciesDetailsNarrative Note 12 - Commitments and Contingencies (Details Narrative) Details http://trunity.co/role/Note10-CommitmentsAndContingencies 38 false false R39.htm 00000039 - Disclosure - Note 13 - Subsequent Events (Details Narrative) Sheet http://trunity.co/role/Note13-SubsequentEventsDetailsNarrative Note 13 - Subsequent Events (Details Narrative) Details http://trunity.co/role/Note11-SubsequentEvents 39 false false All Reports Book All Reports tntyob-20160630.xml tntyob-20160630.xsd tntyob-20160630_cal.xml tntyob-20160630_def.xml tntyob-20160630_lab.xml tntyob-20160630_pre.xml true true ZIP 57 0001575705-16-000167-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001575705-16-000167-xbrl.zip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